Statistical integrative omics methods for disease subtype discovery by Huo, Zhiguang
STATISTICAL INTEGRATIVE OMICS METHODS 
FOR DISEASE SUBTYPE DISCOVERY
by
Zhiguang Huo
M.S in Physics, University of Pittsburgh, 2012
B.S in Physics, Harbin Institute of Technology, China, 2011
Submitted to the Graduate Faculty of
the Department of Biostatistics
Graduate School of Public health in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
University of Pittsburgh
2017
UNIVERSITY OF PITTSBURGH
GRADUATE SCHOOL OF PUBLIC HEALTH
This dissertation was presented
by
Zhiguang Huo
It was defended on
March 30th 2017
and approved by
George C. Tseng, ScD, Professor, Department of Biostatistics, Graduate School of 
Public Health, University of Pittsburgh
YongSeok Park, PhD, Assistant Professor, Department of Biostatistics, Graduate School 
of Public Health, University of Pittsburgh
Abdus S. Wahed, PhD, Associate Professor, Department of Biostatistics, Graduate 
School of Public Health, University of Pittsburgh
Stewart J. Anderson, PhD, Professor, Department of Biostatistics, Graduate School of 
Public Health, University of Pittsburgh
Zhao Ren, PhD, Assistant Professor, Department of Statistics, Dietrich School of Arts 
and Sciences, University of Pittsburgh
ii
Dissertation Director: George C. Tseng, ScD, Professor, Department of Biostatistics,
Graduate School of Public Health, University of Pittsburgh
iii
Copyright c© by Zhiguang Huo
2017
iv
STATISTICAL INTEGRATIVE OMICS METHODS FOR DISEASE
SUBTYPE DISCOVERY
Zhiguang Huo, PhD
University of Pittsburgh, 2017
ABSTRACT
Disease phenotyping using omics data has become a popular approach that can poten-
tially lead to better personalized treatment. Identifying disease subtypes via unsupervised
machine learning is the first step towards this goal. With the accumulation of massive high-
throughput omics data sets, omics data integration becomes essential to improve statistical
power and reproducibility. In this dissertation, two directions from sparse K-means method
will be extended.
The first extension is a meta-analytic framework to identify novel disease subtypes when
expression profiles from multiple cohorts are available. The lasso regularization and meta-
analysis can identify a unique set of gene features for subtype characterization. By adding
pattern matching reward function, consistency of subtype signatures across studies can be
achieved.
The second extension is using integrating multi-level omics datasets by incorporating
prior biological knowledge using sparse overlapping group lasso approach. An algorithm using
alternating direction method of multiplier (ADMM) will be applied for fast optimization.
For both topics, simulation and real applications in breast cancer and leukemia will show
the superior clustering accuracy, feature selection and functional annotation. These methods
will improved statistical power, prediction accuracy and reproducibility of disease subtype
discovery analysis.
v
Contribution to public health: The proposed methods are able to identify disease
subtypes from complex multi-level or multi-cohort omics data. Disease subtype definition
is essential to deliver personalized medicine, since treating different subtypes by its most
appropriate medicine will achieve the most effective treatment effect and eliminate side effect.
Omics data itself can provide better definition of disease subtypes than regular pathological
approaches. By multi-level or multi-cohort omics data, we are able to gain statistical power
and reproducibility, and the resulting subtype definition is much reliable, convincing and
reproducible than single study analysis.
vi
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1.0 INTRODUCTION
In this section, background knowledge for my dissertation is introduced. It contains several
subsections. Genomics background and techniques serves as a overview of datasets used
in this dissertation (Section 1.1). Subtype discovery via transcriptomic data describes the
biological motivation of this dissertation (Section 1.2). Basic bioinformatics approach to
high-throughput genomic data serves as the foundation on which the proposed methods will
depend on (Section 1.3). Statistical omics data integration, including meta analysis and
integrative analysis, serves as the motivation for developing these methods (Section 1.4).
Section 1.5 will give an overview of the dissertation structure and brief introduce the purpose
of each Chapter.
1.1 VARIOUS TYPES OF OMICS DATA
Omics represents the study of genomics, proteomics or metabolomics, which are all with
root -omics. Genomics aims at the collective characterization and quantification of genes,
Omics aims at the collective characterization and quantification of genes, environmental
effect to genes and their interactions. It involves a wide variety of genetic aspects including
transcription, translation, modification, protein-protein interaction and DNA structure, gene
fusion. These genomic phenomena have brought up diverse omics data types. This section
will introduce these types of data at DNA, RNA, epigenetics levels. Properly integrating
these types of omics data and combining data from different sources is very challenging and
my dissertation will solve a couple challenges in this field.
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1.1.1 Omics data at DNA level
Deoxyribonucleic acid (DNA) is a nucleic acid which carries majority of the genetic informa-
tion and controls the development and replication of all living organisms. DNA molecules
are consisted of double strands coiled around each other, with compromised nucleotides on
each base position. Each nucleotide composes one of these nitrogen-containing nucleotides,
guanine (G), adenine (A), thymine (T), or cytosine (C). DNA is a sequence of these nu-
cleotides, which is folded as chromosomes inside nuclear. The human genome contains 46
chromosomes (23 pairs) with approximately 3 billion base pairs of DNA. Fragments of DNA
could be transcripted into messenger RNA, which will form protein sequence and affect the
phenotype of the organism. DNA replicates itself during cell division and the copies of sibling
cells have the identical genetic information as their parent. Single nucleotide polymerphisms
(SNPs) is an inheritable mutation at a single base pair among different members of a pop-
ulation. Common measurement of genetic variations is often referred as SNP genotyping.
Many studies have shown that SNP is associated with phenotypic variation, response to
environment and anthropometric behavior. This type of genetic variation is usually stud-
ied in the whole genome scale and the analysis of SNP is called genome-wide association
study (GWAS). Mutation is a permanent alteration of nucleotide sequence. The resulting
change of DNA is not repairable and the errors will proceed to DNA replication and RNA
transcription. There are two types of major mutations: somatic mutation and germline
mutation. Somatic mutation is a genetic structure variance which is not inheritable from a
parent or to an offspring. It happens all the time for living organisms. Germline mutation
occurs in sperm or ova, which is heritable since it is in the lineage of germ cells. This type
of mutation will be transmitted to offspring. Mutation is associated with cancer since the
error in RNA transcription would result in undesirable protein which could lead to cancer.
Copy number variation (CNV) is a structure variation of DNA segment. It corresponds to
relative long regions of DNA being altered (either duplicated or deleted). DNA is double
strand so normal copy number is 2. Duplicated copy will be greater than 2 and deleted copy
will be smaller than 2. It is observed to relate with diseases and also accounts for regulation
of genes expression and other genomic process.
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1.1.2 Omics data at RNA level
Ribonucleic acid (RNA) is another nucleic acid involved in various biological processes:
coding, regulation and expression of a gene. Although DNA and RNA are all chains of
nucleotides, but RNA is single strand while DNA is double strands. Cellular processes utilize
messenger RNA (mRNA) to transmit genetic information and synthesize proteins. mRNA
plays an important role for many biological process and the amount of mRNA (often called
gene expression) is directed associated to protein formation, external phenotype, cellular
pathway, disease mechanism. mRNA is also called transcriptomic data since it is transcripted
from DNA. Normally the expression of mRNA is positively correlation with CNV of the same
gene, since more copies of DNA tend to transcript more mRNA. But this is not necessarily
true since in reality there are far more complicated biological mechanism which would prevent
the mRNA to be overly expressed given the existence of more copies of DNA. Besides mRNA,
there are other types of RNA, including rRNA, tRNA, snRNA, miRNA. miRNA (short for
microRNA) is a small, non-coding RNA which could regulate gene expression via facilitating
or silencing gene expression. miRNA can target on a group of genes (usually hundreds)
and such predicted information are publicly available in several popular databases (e.g.
http://www.microrna.org/microrna/home.do, http://www.broadinstitute.org/gsea/
msigdb/collections.jsp).
1.1.3 Omics data of epigenetics
Epigenetics include DNA methylation, histone modification and chromatin structure change
and it plays a pivotal role in gene regulation. Although monozygous twins have identi-
cal genotypes, their phenotype may be discordant, such as susceptibilities to disease and
many anthropomorphic features (Fraga et al., 2005), because of the existence of epigenetic
difference. DNA methylation is one of the most crucial epigenetic effects, which will help
regulate the gene expression and silencing(Kulis and Esteller, 2010) and many other cellular
processes, including development of embryo, changing chromatin architecture, inactivation
of X chromosome, genomic imprinting and histone modification (Robertson, 2005). It is
intensely studied and it has been discovered that DNA methylation is correlated with other
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epigenetic effect such as histone modification and changing chromatin architecture. Cancers
are related to the alteration of DNA methylation pattern. For instance, hypermethylation of
tumor suppress genes will inactivate their transcriptional function and lead to loss of regular
cellular function (Esteller, 2007). DNA methylation happens when addition of a methyl
group (-CH3) occurs at the fifth position of the cytosine (C). Most common DNA methy-
lation are observed in CpG dinucleotides, where cytosine (C) is adjacent to guanine (G).
Both microarray technique and NGS technique (see Section 1.1.4) allow us to measure the
methylation value. Commonly the methylation value is measured in a mixture of cells given
a subject. To quantify the methylation level, researchers define beta value, which represents
for a CpG site, the percentage of methylated events out of all methylated and unmethylated
events. As a result, beta value is between 0 and 1. Normally methylation level is negatively
correlated with mRNA expression of the same gene, since the methyl group on DNA usually
inhabits the transcription of mRNA.
1.1.4 Experimental techniques
1.1.4.1 Microarray Traditionally in molecular biology, researchers could only study
some specific genes, which is very time consuming and expensive. DNA Microarray is a
break-through technique that could address this problem that was thought as impossible.
This technique enable researchers to obtain the expression of tens of thousands of genes
simultaneously. This facilitates the biological community to understand the mechanism of
many diseases and fundamental aspects of organ growth and development. A microarray ex-
periment will generate DNA templates which can target specific genes and hybridize mRNA
molecule onto it. And an array is consisted to a lot of DNA samples. The gene expres-
sion level will be evaluated by the amount of mRNA which bound to the DNA templates.
Microarray is also called gene-chips, which has been widely used for decades and its tech-
nique has been updated constantly. It enjoys tremendous popularity for its low cost and
high-throughput (measuring tens of thousands of genes at the same time).
There are three major types of microarray. The first one is expression profiling, in
which mRNA or miRNA expression level could be harvested by using the hybridization
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technique. The detected biomarkers could be hypothesized to be associated with cancer,
other disease, treatment or response to environment. The second type is SNP array detection,
in which single nucleotide polymorphism will be identified. SNP genotyping data and copy
number variation data could be obtained from this type of array. By certain antibody
treatment, methylation level could be detected by this type of array. The third type is
ChIP-chip, which will attach antibodies to protein of interest and immunoprecipitate the
DNA/protein complex. This procedure will help identify binding sites for transcriptional
regulators (including transcription factors, histones and other DNA-binding proteins).
1.1.4.2 Next generation sequencing In the field, the traditional sequencing tech-
nique – Sanger sequencing has been dominating for more than 30 years. In 2001, the Human
Genome Project sequenced the blue print of human genome and it greatly motivated people
to explore our genetic mechanism from a sequencing perspective. However, it is not only
expensive but also only able to target several specified genes. Thus, researchers are hunger
for high throughput techniques. Next generation sequencing utilizes high-throughput DNA
sequencing techniques: DNA sequence are smashed into fragments, which are called reads,
and sequenced in parallel, yielding substantially throughput. Alignment algorithms will as-
semble these short reads to the reference genome. By reconstructing the whole genome, we
are able to know the exact nucleotide order present in DNA and the coverage of of segment
at any position. Therefore a wide variety of genomic features could be measured. Through
specific locus base, we could detect SNP/indel, structural variation and somatic mutation.
Through coverage, we will be able to detect copy number variation and mRNA expression.
By some extra bisulfite treatment technique, sequencing can also measure methylation. Be-
sides novel genomic feature such as isoform of mRNA and fusion genes could be detected.
Nowadays, millions of fragments of DNA from a single sample can be sequenced in parallel
and the entire genome can be sequenced within one day. This technique has dramatically
accelerated people’s understanding about human genome.
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1.1.5 Databases for Omics data
With advances in biological techniques, researchers are able to measure many different types
of omics data. This is often referred as high-throughput technology since relatively small-
size detection equipment could generate large amount of information. Omics datasets are
booming and accumulating in the past 10 years. The price to generate the data keeps
dropping down and large amount of datasets are available in the public domain. Over the
years large amount of omics data are accumulated in public databases and depositories;
for example, The Cancer Genome Atlas (TCGA) http://cancergenome.nih.gov, Gene
Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/, Sequence Read Archive
(SRA) http://www.ncbi.nlm.nih.gov/sra, just to name a few. These datasets provide
unprecedented opportunities to reveal cancer mechanisms via combining multiple cohorts or
multiple-level omics data types (a.k.a. horizontal omics meta-analysis and vertical omics
integrative analysis; see below) (Tseng et al., 2012). My dissertation proposes integrative
and/or meta-analysis approaches to tackle this problem.
1.2 SUBTYPE DISCOVERY VIA TRANSCRIPTOMIC DATA
Many complex diseases were once thought of as a single disease but modern transcriptomic
studies have revealed their disease subtypes that contain different disease mechanisms, sur-
vival outcomes and treatment responses. Representative diseases include leukemia (Golub
et al., 1999), lymphoma (Rosenwald et al., 2002), glioblastoma (Parsons et al., 2008; Ver-
haak et al., 2010), breast cancer (Lehmann et al., 2011; Parker et al., 2009), colorectal cancer
(Sadanandam et al., 2013) and ovarian cancer (Tothill et al., 2008). Taking breast cancer as
an example, Perou et al. (2000) was among the first to apply gene expression profile informa-
tion to identify clinically meaningful subtypes of breast cancer, such as Luminal A, Luminal
B, Her2-enriched and Basal-like. Many independent studies have followed the approach on
different cohorts and identified similar breast cancer subtypes (Ivshina et al., 2006; Loi et al.,
2007; Sørlie et al., 2001; van’t Veer et al., 2002; Wang et al., 2005). Although the breast
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cancer subtype classification models have been shown to cross-validate across studies with
moderately satisfying consistency (Sørlie et al., 2003), each study claims a different intrinsic
gene set (i.e. the list of genes used to define subtype classification) and a different character-
ization of cancer subtypes (Mackay et al., 2011), making it difficult to classify new patients
with confidence in clinical applications. Parker et al. (2009) combined five transcriptomic
studies using pre-existing subtype classifications from each study and identified 50 genes
most reproducible in the subtype classification by Prediction Analysis of Microarray (PAM)
(Tibshirani et al., 2002). These signature genes (often called PAM50) have been widely
followed up and validated thereafter but, from a statistical point of view, the construction of
PAM50 genes was an ad hoc framework and did not fully integrate information of multiple
transcriptomic studies. In a parallel line, Wirapati et al. (2008) performed meta-analysis
of breast cancer subtyping based on three pre-selected genes (ER, HER2 and ERBB2) and
the consequential subtypes were associated with the prior gene selections. These subtypes
usually have strong clinical relevance since they show different clinical outcome, and might
be responsive to different treatments (Abramson et al., 2015). However, single cohort/single
omics (e.g. transcriptome) analysis suffers from sample size limitation and reproducibility
issues (Simon et al., 2003; Simon, 2005; Domany, 2014). Section 1.1.5 describes large amount
of genomic data are available in public domain. By integrating these datasets will increase
statistical power, credibility and reproducibility.
1.3 HIGH-THROUGHPUT GENOMIC DATA ANALYSIS
In this section we will introduce several commonly used high-throughput data analysis meth-
ods. They are also the foundation for methodology development and result evaluation.
1.3.1 Differential expressed gene detection
Differential expressed gene detection is the most commonly used genomics analysis. It could
describe under different environment (case vs control), which gene expression will be altered.
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These detected biomarkers can be further utilized to characterize the disease and predict
the patients. It is also the foundation for other downstream analysis, such as pathway
enrichment analysis machine learning analysis. For continuous expression data including
microarray and RNAseq FPKM data, traditional statistical methods include the student t
test and the Wisconsin rank sum test for two class comparisons. Anova is often applied
to multiple classes comparison and linear regression will be applied to continuous covariate.
Cox proportional hazard model will be suitable for time to event data. However, there are
limitations on traditional methods. For example, with t test, sometimes features with small
effect size could also be chosen because of low variance, through they are not of biological
interest. Advanced method includes SAM (Tusher et al., 2001), LIMMA (Smyth, 2005)
which will partially account for these limitations. For RNAseq count data, edgeR(Robinson
et al., 2010) is a popular tool to detect DE genes. Meanwhile, other omics datatype may have
their own hypothesis. For methylation, people will detect differential methylation using t test
(Hansen et al., 2012) or logistic regression model(Akalin et al., 2012). However these methods
don’t fully account for the design and mechanism of methylation. The Beta binomial model
(Park et al., 2014) will fully characterize these properties. For each of these data setting,
permutation test is also a very powerful approach to detect DE genes. However, it suffers
from heavy computing.
Another problem in differential expressed genes detection is multiple comparison. In
genomics setting, we have at least tens of thousands of features. Assuming there is no DE
signal and all genes are from null. In this case, the p values will be uniformly distributed
between 0 and 1. By chance we will get very signifiant p values. Therefore, we couldn’t simply
use the standard 0.05 p value threshold. To address this problem, there are two multiple
comparison control methods. The first one is family-wise error rate (FWER) (Hochberg and
Tamhane, 2009), which gives the probability of at least one false positive. In genomic setting,
it is often too stringent to control FWER. Another commonly used measurement is false
discovery rate (FDR) (Benjamini and Hochberg, 1995). This indicates within our discoveries,
what the percentage of false positives is. These two multiple comparison procedures are
widely applied in genetics and genomics studies.
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1.3.2 Pathway enrichment analysis
In genomics analysis, we could obtain a list of genes that are related to disease or treatment.
These genes could be differential expression genes (from DE analysis) or co-expression genes
(from cluster analysis). Pathway enrichment analysis is to pursue a functional annotation
for the outcome gene list. A pathway database is a collection of genes, which are known
to be associated with specific biological states, chemical perturbations or other environmen-
tal or treatment factors. A lot commonly used pathway databases can be obtained from
public domain. To list a few, Gene Ontology (GO) http://geneontology.org, KEGG
http://www.genome.jp/kegg/, Biocarta http://www.biocarta.com, Reactome http://
www.reactome.org, MSigDB http://www.broadinstitute.org/gsea/msigdb/index.jsp.
Pathway enrichment result could serve as a validating purpose if the pathway result is highly
associated with the experimental setting,
Several hypothesis testing methods can be used to examine the association between the
experimental outcome gene list and a pathway (a list of pathway genes). Fisher’s exact tests
or Chi-square tests could test this association very well. For these two tests we only need to
use the outcome gene list and don’t need the significance score (p value of each gene). We
could construct a 2 × 2 table by two conditions: whether the gene is in outcome gene list
and whether the gene is in the pathway database. The null hypothesis is the proportion of
outcome genes inside a pathway is independent of the proportion of outcome genes outside
a pathway. Fisher’s exact tests or Chi-square tests can illustrate how significant a outcome
gene proportion is different between inside or outside pathways. Another approach is to
utilize a Kolmogorov-Smirnov test (KS test). For this test, we need to use the gene list
and significance score. The null hypothesis is the distribution of significance score of all
genes inside a pathway is same as the distribution of significance score of all genes outside a
pathway. The KS test could could tell how significant there is a significance score difference
between inside or outside pathways. Pathway enrichment analysis will be used to examine
whether the detected co-expression gene list or DE gene list is biological meaningful in result
sections of later chapters.
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1.3.3 Transcriptomic clustering analysis
1.3.3.1 General clustering analysis algorithms Unsupervised machine learning aims
to group a set of objects into clusters without the prior knowledge of class labels. It is widely
used in genomics research and other machine learning field. Clustering analysis could help
to discover disease subtypes, which could better characterize the disease property and guide
to precision medicine. In the literature, hierarchical clustering (Ward Jr, 1963) generates
clustering result at each level of hierarchy by combining clusters result of the next lower level.
K-means (MacQueen et al., 1967) is popular due to its simplicity and fast computing. It aims
to minimize the within cluster sum of square by iteratively optimize its cluster assignment
and cluster labels. Self organized map (SOM)(Kohonen, 1998) generates clustering diagram
by mapping a high-dimensional distribution to a low-dimensional grid. Mean shift clustering
(Cheng, 1995) performs clustering by seeking for modes through non-parametric iteration. In
terms of transcriptomic clustering analysis, popular methods include hierarchical clustering
(Eisen et al., 1998), K-means (Dudoit and Fridlyand, 2002), mixture model-based approaches
(Xie et al., 2008; McLachlan et al., 2002) and non-parametric approaches (Qin, 2006), for
analysis of single transcriptomic study. Resampling and ensemble methods have been used
to improve stability of the clustering analysis (Kim et al., 2009; Swift et al., 2004) or to
pursue tight clusters by leaving scattered samples that are different from major clusters
(Tseng, 2007; Tseng and Wong, 2005; Maitra and Ramler, 2009). Witten and Tibshirani
(2010) proposed a sparse K-means algorithm that can effectively select gene features and
perform sample clustering simultaneously.
1.3.3.2 K-means and sparse K-means K-means algorithm (Hartigan and Wong,
1979) has been a popular clustering method due to its simplicity and fast computation.
Consider Xjl the gene expression intensity of gene j and sample l. The method aims to
minimize the within-cluster sum of squares (WCSS):
min
C
p∑
j=1
WCSSj(C) = min
C
p∑
j=1
K∑
k=1
1
nk
∑
l,m∈Ck
dlm,j (1.3.1)
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where p is the number of genes (features), K is the number of clusters, C = (C1, C2, . . . , CK)
denotes the clustering result containing partitions of all samples into K clusters, nk is the
number of samples in cluster k and dlm,j = (Xjl − Xjm)2 denotes the squared Euclidean
distance of gene j between sample l and m. Although the initial development of K-means
was a heuristic algorithm, it was shown to be a special classification likelihood method in
model-based clustering when data from each cluster come from Gaussian distribution with
identical and spherical covariance structure (Tseng, 2007).
One major drawback of K-means is that it utilizes all p features with equal weights in
the distance calculation. In genomic applications, p is usually high but biologically only
a small subset of genes should contribute to the sample clustering. Witten and Tibshi-
rani (2010) proposed a sparse K-means approach with lasso regularization on gene-specific
weights to tackle this problem. One significant contribution of their sparse approach was
the observation that direct application of lasso regularization to Equation 1.3.1 will result
in a meaningless null solution. Instead, they utilized the fact that minimizing WCSS is
equivalent to maximizing between-cluster sum of squares (BCSS) since WCSS and BCSS
add up to a constant value of total sum of squares (TSSj = BCSSj(C) +WCSSj(C)). The
optimization in Equation 1.3.1 is equivalent to
max
C
p∑
j=1
BCSSj(C) = max
C
p∑
j=1
[
1
n
∑
l,m
dlm,j −
K∑
k=1
1
nk
∑
l,m∈Ck
dlm,j
]
(1.3.2)
The lasso regularization on gene-specific weights in Equation 1.3.2 gives the following sparse
K-means objective function:
max
C,w
p∑
j=1
wjBCSSj(C)
subject to ‖w‖2 ≤ 1, ‖w‖1 ≤ µ,wj ≥ 0,∀j, (1.3.3)
where wj denotes weight for gene j, C = (C1, . . . , CK) is the clustering result, K is the
pre-estimated number of clusters and ‖w‖1 and ‖w‖2 are the l1 and l2 norms of the weight
vector w = (w1, . . . , wp). The regularization shrinks most gene weights to zero and µ is a
tuning parameter to control the number of non-zero weights (i.e. the number of intrinsic
genes for subtype characterization).
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These methods serve as the background for Chapter 2 and Chapter 3, aim to develop
methodology to discover disease subtypes from omics data.
1.4 STATISTICAL DATA INTEGRATION
As described in Section 1.1.5, large amounts of omics data are accumulating and become
publicly available. How to combine these dataset to strengthen statistical analysis becomes
a natural question. Reproducibility problem is also emphasized in the literature. Ioannidis
et al. (2008) evaluated the replication of 18 microarray-based gene expression analyses, but it
turned out reproducibility was low. Integration of different omics data type and/or different
cohorts will help improve reproducible and draw robust inference. To extend single-study
techniques towards integration of multiple omics data sets, Tseng et al. (2012) categorized
omics data integration into two major types: (A) Horizontal omics meta-analysis and (B)
Vertical omics integrative analysis. Figure 1 has shown two directions for data integration
including horizontal genomics meta analysis and vertical genomic integrative analysis. For
horizontal meta-analysis (Figure 1(a)), multiple studies of the same omics data type (e.g.
transcriptome) from different cohorts are combined to increase sample size and statistical
power, a strategy often used in differential expression analysis (Ramasamy et al., 2008),
pathway analysis (Shen and Tseng, 2010), network analysis (Zhu et al., 2016) or subtype
discovery (Huo et al., 2016). In contrast, vertical integrative analysis (Figure 1(b)) aims to
integrate multi-level omics data from the same patient cohort (e.g. gene expression data,
genome-wide profiling of somatic mutation, DNA copy number, DNA methylation, or mi-
croRNA expression from the same set of biological samples (Richardson et al., 2016)).
1.4.1 Horizontal meta analysis
Horizontal genomics meta analysis aims to combine multiple transcriptomic studies or other
omics data type. Most methods have been developed to improve differential analysis (candi-
date marker detection)(Chang et al., 2013) and pathway analysis(Wang et al., 2012). Hor-
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(a) Horizontal meta-analysis (b) Vertical integration
Figure 1: Background for omics data integration.                                                                          
Meta analysis omics data integration (Horizontal direction) and integrative omics data 
integration (Vertical direction)
izontal genomics meta analysis of differential expressed genes includes method combining p 
value: Fisher(Fisher, 1925), Stoffer(Stouffer, 1949), maxP, minP, roP(Song and Tseng, 2014), 
AW(Li et al., 2011); other approach to combine effect sizes, or Bayesian approach(Scharpf et 
al., 2009). Horizontal genomics meta analysis could increase statistical power and over-come 
the difficulty that signal in single cohort is weak and not that reproducible.
As high-throughput experiments become affordable and prevalent, many data sets of the same 
omic type (e.g. transcriptome) and of a related disease hypothesis have often been col-lected 
and meta-analyzed, as is described in Section 1.4. The meta-analysis to combine mul-tiple 
studies has brought new statistical challenges. When multiple transcriptomic studies are 
combined, most methods have been developed to improve differential analysis (candidate 
marker detection) and pathway analysis (See Section 1.4). These methods mostly extend from 
traditional meta-analysis by combining effect sizes or p-values of multiple studies to a 
genome-wide scale (see review papers for microarray and GWAS meta-analysis by (Tseng et 
al., 2012; Begum et al., 2012) for details).
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1.4.2 Vertical integrative analysis
Vertical genomic integrative analysis aims to integrate multiple types of omics data from a
given cohort. The input omics data source include but not limit to transcriptome profile,
genotypes, DNA copy number alteration, DNA methylation, microRNA and proteinomics.
For instance, IBAG (Wang et al., 2013) uses model-based integration approach, combin-
ing data obtained from multiple platforms into one integrative model to discover clinically
relevant biomarker and/or to predict clinical outcome. Icluster (Shen et al., 2009) uses di-
mension reduction and latent variable techniques to combine different omics data and find
disease subtypes. Vertical genomic integrative analysis will make the result more consistent
within cohort and biological meaningful. Meanwhile by recruiting different sources of omics
data, statistical power will increase and the conclusion will be more convincing.
1.5 OVERVIEW OF THE DISSERTATION
My dissertation contains six chapters. Chapter 1 contains overall introduction of datasets,
experimental techniques, high through-put analysis methods, motivation of genomic inte-
grative analysis. These contents serve as the background knowledge for the methodology
development for Chapter 2, 3.
Chapter 2 is Meta-analytic framework for sparse K-means to identify disease subtypes
in multiple transcriptomic studies. This is a meta-analysis framework for disease subtyping
combining multiple omics cohorts. Intuitively, this method is better than single study sparse
Kmeans since meta analysis will achieve unified feature selection; increase credibility of
inference by recruiting more studies. It has also been shown to have better performance,
including clustering accuracy in simulation and resampling accuracy and stability in real
data application than single study sparse clustering. The content in this Chapter has been
published in Journal of the American Statistical Association (Huo et al., 2016).
Chapter 3 is integrative sparse Kmeans to identify disease subtypes form multiple omics
data types of the same patient cohort. This integrative approach via combining multiple
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omics data types will better characterize the disease subtypes. We also consider external
group information, which makes the selected for the disease subtype more meaningful. Per-
formance will be evaluated in simulation and real data comparing to sparse Kmeans without
group, or other integrative approach such as iCluster. The content of this chapter is accepted
by the Annals of Applied Statistics (Huo and Tseng, 2017).
Chapter 4 is discussion and future work. The future work is about two way integration to
identify disease subtypes form multiple omics data types from multiple patient cohorts. This
is an extension from both Meta Sparse Kmeans and integrative Sparse Kmeans approach. It
combines all the benefits from Chapter 2 and Chapter 3. by combining multiple omics data
types and multiple cohorts and incorporating external group information, feature selection
and clustering matching. This method would give a comprehensive representation of the
clustering result, which will lead to the most convincing result.
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2.0 META SPARSE KMEANS
2.1 INTRODUCTION
In section 1.2, we introduced the background for disease subtype discovery via transcrip-
tomic data. With the accumulation of transcriptomic data in public domain, we will gain
statistical power and reproducibility by combining multiple studies. In section 1.3.3.1, we
introduced popular transcriptomic clustering method for single study. But when it comes to
disease subtype discovery, no integrative method for combining multiple transcriptomic stud-
ies is available, to the best of our knowledge. In this chapter, we propose a Meta-analytic
sparse K-means method (MetaSparseKmeans) (Huo et al., 2016) for combining multiple
transcriptomic studies, which identifies disease subtypes and associated gene signatures, and
constructs prediction models to classify future new patients. The method contains embedded
normalization and scaling to account for potential batch effects from different array plat-
forms and a multi-class correlations (MCC) measure (Lu et al., 2010) to account for different
sample proportions of the disease subtypes across studies. A pattern matching reward func-
tion is included in the objective function to guarantee consistency of subtype patterns across
studies. We will demonstrate improved performance of MetaSparseKmeans by simulations
and two real examples in leukemia and breast cancer studies. The content in this Chapter
has been published in Journal of the American Statistical Association (Huo et al., 2016).
This chapter is structured as the following. In Section 2.2, we will demonstrate a motivat-
ing example to combine three large breast cancer transcriptomic studies for disease subtype
discovery. We will describe the input data structure, problem setting and the biological
goals to motivate the development of MetaSparseKmeans. In Section 2.3, introduction of
classical K-means, sparse K-means and development of MetaSparseKmeans are presented.
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Section 3.4 contains simulation results and applications to real data in breast cancer and
leukemia. Finally, conclusions and discussions are included in Section 3.5.
2.2 MOTIVATING EXAMPLE
Table 1 shows a summary description of three breast cancer training transcriptomic studies:
Wang (Wang et al., 2005), Desmedt (Desmedt et al., 2007) and TCGA (Network, 2012) as
well as one testing study METABRIC (Curtis et al., 2012) with large sample size (n=1981)
and survival information. In the training set, each study contains about 150-500 samples.
Wang and Desmedt applied Affymetrix U133A chip that generated log-intensities ranging
between 2.104 and 14.389, while TCGA adopted Agilent Custom 244K array that produced
log-ratio intensities ranging between -13.816 and 14.207. All probes in three studies were
matched to gene symbols before meta-analysis. When multiple probes matched to one gene
symbol, the probe that with the largest inter-quartile range (IQR) was used (Gentleman
et al., 2005). 11,058 genes were matched across studies and three gene expression matri-
ces (11,058×260, 11,058×164 and 11,058×533) were used as input data for disease subtype
discovery. In such a meta-analysis framework of sample clustering analysis, we pursue two
goals simultaneously: identification of a gene set (often called “intrinsic gene set”) for sub-
type characterization and clustering of samples in each study. Five major analytical issues
(or procedures) have to be considered in the new meta-analytic framework: (A) combine in-
formation from multiple studies and perform feature (gene) selection; (B) use the combined
information to perform clustering on each study; (C) accommodate potential batch effect
across studies and the fact that each study contains different mixture proportions of the
subtypes. (e.g. study 1 contains 20% of the first subtype while study 2 contains 35%); (D)
guarantee that subtypes across studies can be matched with consistent gene signature and
pattern; (E) construct a prediction model based on the combined analysis to predict future
patients. In the following method section, we will develop a MetaSparseKmeans method to
answer all five issues described above. Figure 2(d)-2(f) illustrate the heatmap result of our
developed method on the motivating example (details will be discussed in the Result Sec-
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Table 1: Breast Cancer Data information
Training Testing
Study Name TCGA Wang at el. Desmedt at el. METABRIC
Platform Agilent Affymetrix Affymetrix Illumina
Number of genes 17,814 12,704 12,704 19,602
Number of patients 533 260 164 1,981
Range of intensity [−13.816, 14.207] [3.085, 14.389] [2.104, 14.160] [-1.262 16.618]
Mean intensity 0.003 6.797 5.523 6.954
Standard deviation 1.34 1.71 1.84 1.70
tion 2.4.3). 203 genes (on the rows of heatmaps) were simultaneously selected to characterize
the disease subtypes. Clustering results were shown on the color bars above the heatmaps.
The expression patterns of the five disease subtypes were matched well across studies from
visual inspection in the heatmaps and a classification model was constructed to predict fu-
ture patients. In contrast, Figure 2(a)-2(c) show sparse K-means clustering results when
applied to each study separately. Each study generates different gene selection (220, 197,
239 genes respectively) and cluster patterns that are difficult to be integrated to predict a
future patient. Throughout this chapter, we will develop and illustrate the method for com-
bining multiple transcriptomics studies, but the method is also applicable to meta-analysis
of other types of omics data, such as miRNA, methylation or copy number variation.
2.3 METHOD
2.3.1 MetaSparseKmeans
We have introduced K-means and sparse K-means in Section 1.3.3.2. Equation 1.3.3 identi-
fies gene features and performs sample clustering simultaneously for a given transcriptomic
study. To extend it for combining S(S ≥ 2) transciptomic studies, a naive solution is to
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(a) TCGA (239 genes) (b) Wang at el. (220 genes) (c) Desmedt at el. (197 genes)
(d) TCGA (203 genes) (e) Wang at el. (203 genes) (f) Desmedt at el. (203 genes)
Figure 2: Individual study clustering and MetaSparseKmeans result for 3 breast cancer
datasets.
Rows represent genes and columns represent samples. Red and green color represent higher
and lower expression. In each study, the patients are divided into 5 clusters, represented by
5 unique colors in the color bar above the heatmaps. 2(a)-2(c): Sparse K-means result from
three studies separately. 2(d)-2(f): MetaSparseKmeans result.
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consider optimization of the sum over S studies:
arg max
C(s),z
p∑
j=1
zj ×
S∑
s=1
BCSS
(s)
j (C
(s))
subject to ‖z‖2 ≤ 1, ‖z‖1 ≤ µ, zj ≥ 0,∀j.
(2.3.1)
where superscript of (s) in BCSS(s) and C(s) denotes the BCSS and clustering in study s
(1 ≤ s ≤ S). A notable feature of Equation 2.3.1 is that the weights zj are identical across
all studies and thus it generates a common intrinsic gene set together with clustering of
samples in each study C(s) = (C
(s)
1 , · · · , C(s)Ks) (Ks is the number of clusters in study s). In
this chapter, Ks is assumed to be equal to K (equal number of clusters across studies) and
its extension is discussed later. A downside for Equation 2.3.1 is that it treats all studies
equally without considering that different studies may contain different sample sizes and
intensity ranges as shown in Table 1. As a result, studies with larger sample sizes and higher
intensity variability ranges will dominate the analysis in Equation 2.3.1. To fix this problem,
we propose to standardize BCSS score by TSS below:
arg max
C(s),z
p∑
j=1
zj ×
S∑
s=1
1
S
BCSS
(s)
j (C
(s))
TSS
(s)
j
subject to ‖z‖2 ≤ 1, ‖z‖1 ≤ µ, zj ≥ 0,∀j.
(2.3.2)
Note that the standardized BCSS score in each study is always bounded between 0 and
1. The formulation so far answers issues (A)-(C) in Section 2.2 by generating a common
intrinsic gene set, clustering samples in each study and accommodating different sample sizes
and intensity ranges among studies. In Equation 2.3.2, the contribution of BCSS/TSS is
equal from each study and is not adjusted by sample size (denoted as equal weight or EW).
Alternative option is to replace the 1/S term with ns/
∑
s ns (ns is the sample size of study
s) so that studies with larger sample size contribute greater in the clustering formation
(denoted by unequal weight or UW). In the simulation section (Figure 5), EW and UW are
compared. Conceptually, when studies are homogeneous, UW performs better by accounting
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for sample size. But when studies contain heterogeneous information, EW is expected to be
more robust and will be recommended in real applications.
A next issue in this meta-analytic framework is to match the cluster patterns obtained
from different studies (issue (D) in Section 2.2). For example, samples of the light blue
cluster in all three studies in Figure 2(d)-2(f) are up-regulated (red) in the upper part of
genes and down-regulated (green) in the lower part of genes. Equation 2.3.2 guarantees
to generate sample clusters with good separability in each study but does not warrant such
subtype matching across studies. To achieve this purpose, we added pattern matching reward
function fmatchj (M) in the objective function:
max
C(s),z,M
p∑
j=1
zj ×
[
1
S
S∑
s=1
BCSS
(s)
j (C
(s)(K))
TSS
(s)
j
+ λ× fmatchj (M)
]
subject to ‖z‖2 ≤ 1, ‖z‖1 ≤ µ, zj ≥ 0,∀j,
(2.3.3)
where M is the cluster matching enumeration across S studies, M = M(C(1), . . . , C(S)). For
example, when S = 3 and K = 3, denote (C
(1)
1 −C(2)3 −C(3)1 , C(1)2 −C(2)2 −C(3)3 , C(1)3 −C(2)1 −
C
(3)
2 ) as a possible matching function of M , where the first cluster in study 1, the third
cluster in study 2 and the first cluster in study 3 are matched with similar gene expression
pattern to represent the first disease subtype. Similarly, patients in the second clusters in
study 1, second cluster in study 2 and third cluster in study 3 form the second disease
subtype and so on. Under this notation, the total number of possible pattern matching of
M is (K!)(S−1). M can be regarded as a cluster label reordering operator for all S studies:
M = (φ(1)(C(1)), φ(2)(C(2)), . . . , φ(S)(C(S))), where φ(s)(C(s)) maps the K clusters in the sth
study C(s) = (C
(s)
1 , C
(s)
2 , . . . , C
(s)
K ) to disease subtype 1, 2, . . . , K. In the example above,
the corresponding mapping is φ(1)(C
(1)
1 , C
(1)
2 , C
(1)
3 ) = (1, 2, 3), φ
(2)(C
(2)
1 , C
(2)
2 , C
(2)
3 ) = (3, 2, 1),
φ(3)(C
(3)
1 , C
(3)
2 , C
(3)
3 ) = (1, 3, 2).
The pattern matching reward function fmatchj (M) borrows the concept from multi-class
correlation (MCC) (Lu et al., 2010) that was developed to quantify concordant multi-class
(more than two classes) expression pattern for candidate marker detection in the meta-
analysis of multiple transcriptomic studies. Traditionally, one can calculate the Pearson
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(a) gene CENPA with similar pattern in all studies
(b) gene TUBGCP4 with discordant pattern in different studies
Figure 3: Two real gene examples to show the idea of MCC.
The x axis is the cluster index and y axis is the expression intensity. Gene CENPA shows
similar patterns across studies and MCCs are large (Figure 3(a)). Gene TUBGCP4 shows
discordant patterns across studies and MCCs are smaller (Figure 3(b)).
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correlation of two vectors with equal lengths. However, our pattern matching score needs
to consider the correlation of identical number of clusters with unequal number of samples
in each cluster. For example, Figure 3(a) shows the expression pattern of a given gene
CENPA in the three breast cancer studies, each with 5 clusters of samples. All studies have
relatively high expression in cluster 5, intermediate expression level in cluster 2 and 3, and
lower expression in cluster 1 and 4. This is our desired concordant pattern gene which would
generate high total MCC scores. Figure 3(b) shows a gene with different cluster patterns in
different studies. In Wang the pattern is higher expression in cluster 1, 3 and 4, and lower
expression in cluster 2 and 5. The TCGA study, however, does not have a clear pattern.
Desmedt is somewhat similar to Wang but very different from TCGA. Since the patterns
are not consistent across studies, the total MCC scores in this case should be lower.
Below we describe the MCC score definition from the empirical distributions of each
cluster in a pair of studies study (See Lu et al. (2010) for more details). Consider DX = {xki}
(1 ≤ k ≤ K, 1 ≤ i ≤ nk) to represent expression intensity of class k and sample i for the
first study and DY = {ykj} (1 ≤ k ≤ K, 1 ≤ j ≤ mk) for the second study, where nk
and mk are the number of samples of class k in the first and second studies. We first
define an imaginary bivariate distribution (X,Y) that is a mixture of the K independent
bivariate distributions (X1, Y1), . . . , (XK , YK) with equal probability where Xk and Yk are
empirical distributions from {xk1, . . . , xknk} and {yk1, . . . , ykmk}
(
i.e. the CDF of (X,Y) is
GX,Y(x, y) =
1
K
∑K
k=1 GXk,Yk(x, y) =
1
K
∑K
k=1 GXk(x)GYk(y)
)
. MCC score is defined as the
Pearson correlation of X and Y as shown below
MCC(DX , DY ) = cor(X,Y) =
(
K∑
k=1
µXkµYk)−Kµ¯X µ¯Y√[ K∑
k=1
σ2Xk +
K∑
k=1
(
µXk − µ¯X
)2][ K∑
k=1
σ2Yk +
K∑
k=1
(
µYk − µ¯Y
)2]
,where µXk =
∑nk
i=1 xki/nk, µYk =
∑mk
j=1 ykj/mk, σ
2
Xk
=
∑nk
i=1
(
xki − µXk
)2
/nk, σ
2
Yk
=∑mk
j=1
(
ykj − µYk
)2
/mk, µ¯X =
∑K
k=1 nkµXk/
∑K
k=1 nk, µ¯Y =
∑K
k=1 mkµYk/
∑K
k=1 mk.
It is worth noting that MCC is defined from conventional Pearson correlation and is
restricted between −1 and 1. When n1 = . . . = nk = n and m1 = . . . = mk = m, MCC
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reduces to
MCC =
r~µX~µY√
1
FX
· K
K−1 + 1
√
1
FY
· K
K−1 + 1
,where r~µX~µY =
∑
k(µXk−µ¯X)(µYk−µ¯Y )√∑
k(µXk−µ¯X)2
√∑
k(µYk−µ¯Y )2
is the sample correlation of ~µX = (µX1 , . . . , µXk)
and ~µY = (µY1 , . . . , µYk). FX =
∑
k(µXk−µ¯X)2/(K−1)∑
k
∑
i(xki−µXk )2/
(
(n−1)K
) and FY = ∑k(µYk−µ¯Y )2/(K−1)∑
k
∑
j(ykj−µYk )2/
(
(m−1)K
)
are exactly the F-statistics in ANOVA for DX and DY . When the within-class variation is
much smaller than the between-class variation, FX and FY become large. MCC converges
to r~µX~µY as expected.
Finally, the pattern matching reward function is defined as the average of MCC of all
pairs of studies as below:
fmatchj (M) =
(
1(
S
2
) ∑
s,s′∈S
MCCj(φ
(s)(C(s)), φ(s
′)(C(s
′))) + 1
)
/2
where s and s′ denote any two studies from all S studies and φ(s)(C(s)) was previously
defined for cluster matching function M . Note that the pattern matching reward function
is transformed to guarantee taking values between 0 and 1.
In summary, the objective function of MetaSparseKmeans in Equation 2.3.3 generates
a common feature set from the non-zero estimated weights and sample clustering in each
study. The first term in Equation 2.3.3 ensures good cluster separation in each study, the
second term guarantees the consistent patterns of identified disease subtypes across studies
and the l1 penalty generates sparsity on gene weights to facilitate feature selection.
2.3.2 Implementation of MetaSparseKmeans
In this subsection, we discuss the optimization procedure, parameter estimation and how
the classification model from the clustering can predict a future patients cohort.
2.3.2.1 Optimization without pattern matching reward function For clarity of
demonstration, we first illustrate the optimization procedure without reward function as
shown in Equation 2.3.2. The algorithm is a simple extension from Witten and Tibshirani
(2010).
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1. Initialize z such that zj =
sdj
sd1+...+sdp
× µ, where sdj is the standard deviation of gene j.
2. Fix z, update C(s) for study s (∀s ∈ S) by optimizing Equation 2.3.2 applying conven-
tional weighted K-means.
3. Fix C(s), update z by optimizing Equation 2.3.2 following Karush-Kuhn-Tucker (KKT)
condition.
4. Iterate Step 2-3 until converge.
In Step 1, we apply unequal initialization weight that is proportional to the standard de-
viation of each gene. We have found better performance of this initialization compared to
equal weight initialization suggested in (Witten and Tibshirani, 2010). In Step 2, since the
weights are fixed and TSS
(s)
j is irrelevant to the clustering result, the optimization is es-
sentially to repeat regular K-means algorithm with weighted gene structure for each study
independently. In Step 3, fixing aj =
∑S
s=1
BCSS
(s)
j (C
(s)(K))
TSS
(s)
j
, optimization of weights z is a
convex optimization problem that leads to zj =
Γ∆(aj)
‖Γ∆(aj)‖2 following KKT condition, where
Γ is the soft-thresholding operator which is defined as Γ∆(x) = max(x − ∆, 0). ∆ > 0 is
chosen such that ‖z‖1 = µ; otherwise ∆ = 0 if ‖z‖1 < µ. Readers may refer to (Boyd and
Vandenberghe, 2004; Witten and Tibshirani, 2010) for more details. Finally, Steps 2 and 3
are iterated until convergence of the weight estimate (i.e.
∑p
j=1 |z(r)j −z(r−1)j |∑p
j=1 |z(r−1)j |
< 10−4), where z(r)j
represents the zj estimate in the r
th iteration. In our simulation and real data experiences,
the algorithm usually converges within 20 iterations.
2.3.2.2 Optimization with pattern matching reward function When the pattern
matching reward function is added, the iterative optimization has an additional step to
estimate the best clustering matching across studies M. In this case we split optimization of
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Equation 2.3.3 into 3 parts:
C(s)+ = arg max
C(s)
p∑
j=1
zj ×
[
1
S
S∑
s=1
BCSS
(s)
j (C
(s))
TSS
(s)
j
]
(2.3.4a)
M+ = arg max
M
p∑
j=1
zj × fmatchj (M) (2.3.4b)
z+ = arg max
z
p∑
j=1
zj ×
[
1
S
S∑
s=1
BCSS
(s)
j (C
(s))
TSS
(s)
j
+ λ× fmatchj (M)
]
subject to ‖z‖2 ≤ 1, ‖z‖1 ≤ µ, zj ≥ 0,∀j, (2.3.4c)
where C(s)+,M+, z+ are the updating rule in the iteration. The optimization algorithm
becomes:
1. Initialize z such that zj =
sdj
sd1+...+sdp
× µ, where sdj is the standard deviation of gene j.
2. Fix z, for ∀s ∈ S, update C(s) by weighted K-means according to Equation 2.3.4a.
3. Fix z and C(s), update M by using exhaustive search or simulated annealing (see below)
according to Equation 2.3.4b.
4. Fix C(s) and M , update z by KKT condition according to Equation 2.3.4c.
5. Iterate Step 2-4 until converge.
One potential concern in Equation 2.3.4a is the lack of consideration of fmatchj (M). In-
cluding fmatchj (M) in Equation 2.3.4a will greatly complicate the optimization for C
(s). We
decided to remove this term so that C(s) can be efficiently estimated in each study separately
and then update M right after updating C(s). The simplified algorithm performed well in
all our applications.
When updating M in Equation 2.3.4b, exhaustive search requires evaluation of all pos-
sible (K!)S−1 combinations. In our motivating example of K = 5 and S = 3, it takes 14,400
evaluations. The number of evaluations increases to 207.36 million when S increases to 5.
As an alternative, we propose a linear stepwise search to reduce the computational burden.
In the first step, we match the first two studies with the largest sample sizes. Then the
third study is added to match with existing patterns and the procedure continues by adding
one study at a time. This approach will reduce to (K!)× (S − 1) possible evaluations. The
search space will reduce from exponential order to linear order of the number of studies. In
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the case of K = 5 and S = 5, the number of evaluations reduces from 207.36 million to
480. In case that the linear stepwise search may reach an undesirable suboptimal solution,
we propose a third approach to apply stepwise search solution as an initial value to a simu-
lated annealing algorithm (Kirkpatrick et al., 1983) (see Appendix for detailed algorithm).
Simulated annealing is an MCMC-based stochastic optimization algorithm for non-convex
function. We expect that the third approach will achieve the best balance for affordable
computing time while maintaining high clustering accuracy (Table ??). The computing load
and performance of these three matching approach will be evaluated in Section 2.4.4. In
our software package, we suggest to perform exhaustive search when (K!)S−1 ≤ 14, 400 and
automatically switch to simulated annealing otherwise.
2.3.2.3 Parameter selection In the MetaSparseKmeans formulation above, the num-
ber of clusters K are assumed pre-specified. In practice, it has to be estimated from data.
The issue of estimating the number of clusters has received wide attention in the litera-
ture (Milligan and Cooper, 1985; Kaufman and Rousseeuw, 2009; Sugar and James, 2003).
Here, we suggest the numbers of clusters to be estimated in each study separately using
conventional methods such as prediction strength (Tibshirani and Walther, 2005) or gap
statistics (Tibshirani et al., 2001) and jointly compared across studies (such that the num-
bers of clusters are roughly the same for all studies) for a final decision before applying
MetaSparseKmeans. Below we assume that a common K is pre-estimated for all studies.
Another important parameter to be estimated is µ that controls the number of non-zero
weights in the lasso regularization. Larger µ results in larger number of non-zero weights
(i.e. the number of intrinsic genes to characterize the subtypes). We follow and extend the
gap statistic procedure in sparse K-means (Witten and Tibshirani, 2010) to estimate µ:
1. For each gene feature in each study, randomly permute the gene expression row vector
(permute samples). This creates a permuted data set X(1). Repeat for B times to
generate X(1), X(2), . . . , X(B).
2. For each potential tuning parameter µ, compute the gap statistics as below.
Gap(µ) = O(µ)− 1
B
B∑
b=1
Ob(µ), (2.3.5)
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where O(µ) =
∑p
j=1 z
∗
j [
1
S
(
∑S
s=1
BCSS
(s)
j (C
(s)∗(K))
TSS
(s)
j
)+λ×fmatchj (M∗)] is from observed data,
where z∗, C∗(K),M∗ are the maximizers of the objective function. Ob(µ) is similar to
O(µ) but it is from permuted data X(b)
3. For a range of selections of µ, select µ∗ such that the gap statistics in Euqation 3.3.6 is
maximized. Figure 11 shows the candidate region and the corresponding gene numbers
of different µ for a simulated dataset that will be discussed in Section 3.4.1.
Figure 4: Gap statistics to select µ in simulated data with biological variance σ1 = 1.
X-axis: µ; y-axis: gap statistics. V and µ on top give the number of non-zero weight 
features and corresponding tuning parameter. Gap statistics is maximized at µ = 9, which 
is coresponding to 151 genes.
Our simulation has shown good performance of the gap statistics procedure but the 
performance may vary in real data. In practice, the users may test different selections of µ and 
examine the change of clustering assignment. In general, slight change of µ (or equivalently 
the number of selected genes) does not greatly change the clustering result. Another 
possibility is to use clinical or survival information to guide estimation of µ although we chose 
not to do so in the breast cancer example to avoid re-using the survival information in the 
evaluation.
28
Finally, the parameter λ controls the balance of the standardized BCSS and pattern 
matching rewards in Equation 2.3.3. The former term drives the optimization to seek for 
clear cluster separations while the latter term emphasizes on concordant pattern of disease 
subtypes across studies. We performed sensitivity analysis on λ in the applications and 
found that slightly changing λ had little impact on the final clustering result in most cases. 
Since considerations of both terms are biologically important, we suggest to use λ = 0.5 in 
general unless users have particular reasons to change. Note that the first and second terms 
in Equation 2.3.3 are standardized to range between 0 and 1 and are at comparable scales.
2.3.2.4 Data visualization To generate heatmaps similar to Figure 2(a)-2(f), data nor-
malization is necessary so genes at different expression scales can be presented simultane-
ously. Conventional wisdom in microarray analysis is to standardize each gene vector to have 
zero mean and unit variance in each study independently. This is, however, not applicable 
in our situation since the sample proportions of each disease subtype are not equal across 
studies. We instead applied a ratio-adjusted gene-wise normalization (Cheng et al., 2009) 
that accounts for differential subtype mixture proportions in the studies.
2.3.2.5 Classification of a future patient cohort For a future dataset that possibly 
comes from a different experimental platform, models from MetaSparseKmeans can help 
cluster the new cohort and match the signature patterns to determine the subtypes. The 
algorithm goes with two steps:
1. The optimal weights z∗ from MetaSparseKmeans algorithm on training data are used
to cluster patients of the new cohort using conventional K-means with pre-specified
weighted gene structure:
C(new) = arg min
C
p∑
j=1
z∗j
K∑
k=1
1
nk
∑
l,m∈Ck
dlm,j
2. The generated clusters C(new) are then matched back to disease subtypes determined
by MetaSparseKmeans training results. Specifically, we ask for the best cluster pattern
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matching of the new clusters to the original subtypes. Since the matching in the train-
ing studies are fixed, the optimization only requires MCC calculation of new cohort
clustering C(new) with clustering of each training study C(1), . . . , C(S).
M (new∗) = arg max
M(new)
p∑
j=1
∑
s∈S
z∗jMCCj(φ
(s)(C(s)), φ(new)(C(new)))
2.3.2.6 Extensions for practical applications Below we discuss two extensions for
practical applications. Firstly, our framework has applied equal K in all studies. The
question is whether and how to allow variable K across studies. Biologically, it is not
reasonable to have wildly different number of disease subtypes across studies. Thus, we
decided not to extend the algorithm for automatically searching variable K. Instead, we
suggest the users to apply equal K and perform ad hoc analysis if evidence shows that some
studies have almost no samples for a particular subtype or an additional subtype is needed
(e.g. reduce from K=(5,5,5) to K = (5, 4, 5) in the second study). Secondly, the number
of genes may reduce greatly in the gene matching step if one or two studies apply an old
array platform with less comprehensive coverage of the genome. In this case, our framework
can easily extend to allow missing genes in partial studies (by simply ignoring the terms of
a specific missing gene in a study). We have included this function in the software package
and suggest to include genes as long as they appear in > 70% of studies.
2.4 RESULT
We evaluated MetaSparseKmeans on simulation datasets as well as two real multi-center
examples in leukemia and breast cancer. In the simulation datasets, we showed that
MetaSparseKmeans could recover the underlying true clusters with higher accuracy than
single study analysis. We also showed that MetaSparseKmeans using equal weight (EW)
is superior than MetaSparseKmeans using unequal weight (UW) in heterogenous scenario
and reversely MetaSparseKmeans UW is superior than MetaSparseKmeans EW in homoge-
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nous scenario. In leukemia dataset, we demonstrated that MetaSparseKmeans obtained
unified gene selection and stable cluster pattern while single study analysis by sparse K-
means claimed different gene selections and unmatched cluster patterns in different studies.
In the breast cancer dataset, we applied MetaSparseKmeans to 3 breast cancer studies
and showed that MetaSparseKmeans had better performance than single study sparse K-
means. The classification model was used to predict the fourth METABRIC dataset and
the meta-analyzed model generated more significant survival differences than the prediction
based on single study models. Lastly we evaluated the computation time and accuracy for
MetaSparseKmeans using different matching algorithm. MCMC (with linear stepwise search
initial) will balance the computing load and optimization performance.
2.4.1 Simulation
2.4.1.1 Simulation setting To evaluate the performance of MetaSparseKmeans and
compare with sparse K-means, we simulated S(S = 3) studies with K(K = 3) subtypes
in each study. To best mimic the nature of microarray study, we will simulate confounding
variables, gene correlation structure and noise genes (e.g. housekeeping genes or unexpressed
genes). Below are the detailed generative steps to create subtype predictive genes, confounder
impacted genes and noise genes.
(a) Subtype predictive genes.
1. We simulate Nk1 ∼ POI(400), Nk2 ∼ POI(200), Nk3 ∼ POI(100) samples for subtype
k(1 ≤ k ≤ 3) in study s(1 ≤ s ≤ 3). The number of subjects in study s is Ns =∑
kNks.
2. Sample M = 20 gene modules (1 ≤ m ≤ 20). In each module, sample nm genes where
nm ∼ POI(20). Therefore, there will be an average of 400 subtype predictive genes.
3. µsik is the template gene expression of study s(1 ≤ s ≤ S), subtype k(1 ≤ k ≤ 3) and
module m(1 ≤ m ≤ M). For the first study, sample the template gene expression
µ1km ∼ UNIF(4, 10) with constrain maxp,q |µ1pm − µ1qm| ≥ 1, where p, q denote two
subtypes. For the second and third study, set µ2km = µ3km = µ1km,∀k,m. This part
define the subtype mean intensity for each module in all studies. To simulate the
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situation that the first study (with the largest sample size) containing stronger signal,
we introduced a new parameter f (for fold) to recalculate the template gene expression
for the first study µ1km: µ
?
1km = (µ1km −mink,m{µ1km})× f + mink,m{µ1km}, We set
f = 1 unless otherwise mentioned.
4. Add biological variation σ21 to the template gene expression and simulate X
′
skmi ∼
N(µskm, σ
2
1) for each module m, subject i(1 ≤ i ≤ Nks) of subtype k and study s.
5. Sample the covariance matrix Σmks for genes in module m, subtype k and study s,
where 1 ≤ m ≤ 20, 1 ≤ k ≤ 3 and 1 ≤ s ≤ 3. First sample Σ′mks ∼ W−1(Φ, 60),
where Φ = 0.5Inm×nm + 0.5Jnm×nm , W
−1 denotes the inverse Wishart distribution, I
is the identity matrix and J is the matrix with all elements equal 1. Then Σmks is
calculated by standardizing Σ
′
mks such that the diagonal elements are all 1’s.
6. Sample gene expression levels of genes in cluster m as (X1skmi, . . . , Xnmskmi)
> ∼
MVN(X
′
skmi,Σmks), where 1 ≤ i ≤ Nks, 1 ≤ m ≤M , 1 ≤ k ≤ 3 and 1 ≤ s ≤ 3.
(b) Confounder impacted genes.
1. Sample 4 confounding variables. In practice, confounding variables can be gender,
race, other demographic factors or disease stage etc. They will add heterogeneity to
each study to complicate disease subtype discovery. For each confounding variable c,
we will sample R = 15 modules. For each of these modules rc(1 ≤ rc ≤ R), sample
number of genes nrc ∼ POI(20). These genes will be the same for all 3 studies.
Therefore, there will be an average of 1,200 confounder impacted genes.
2. For each study s(1 ≤ s ≤ 3) and each confounding variable c, sample the number of
confounder subclass hsc ∼ POI(3) with constraint hsc > 1. The Ns samples in study
s will be randomly divided into hsc subclasses.
3. Sample confounding template gene expression µslrc ∼ UNIF(4, 10) for confounder
c, gene module r, subclass l(1 ≤ l ≤ hsc) and study s. We recalculate µ?1lrc =
(µ1lrc −minlrc{µ1lrc}) × f + minlrc{µ1lrc}, which is similar to Step 3. Add biological
variation σ21 to the confounding template gene expression X
′
scrli ∼ N(µslrc, σ21). Similar
to Step 6 and 7, we simulate gene correlation structure within modules of confounder
impacted genes.
(c) Noise genes.
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1. Sample 8,400 noise genes denoted by g(1 ≤ g ≤ 8, 400). For each study, we gener-
ate the mean template gene expression µsg ∼ UNIF(4, 10). Then we add biological
variation variance σ22 = 1 to generate Xsgi ∼ N(µsg, σ22), 1 ≤ i ≤ Ns. Gene expres-
sion level generated here will be relatively stable. Therefore these genes could be
regarded as housekeeping genes if their expression are high, or un-expressed genes if
their expression are low.
2.4.1.2 Simulation result In this section we compared the performance of
MetaSparseKmeans using equal weight (EW) and unequal weight (UW), and compared
metaSparseKmeans with single study sparse K-means result. The tuning parameter for
MetaSparseKmeans was selected from gap statistics. For a fair comparison, we selected the
tuning parameter in single study such that the number of selected genes are similar to the
number in MetaSparseKmeans. We compared the results by adjusted Rand index (Hubert
and Arabie, 1985) (ARI) with the underlying truth in each study. The ARIs were averaged
over 3 studies. Figure 5(a) shows the performance of three methods for B = 100 simulations
and σ1 = 0.6, 0.8 ∼ 3 (error bars represent mean ± standard error). When the biolog-
ical variation increases, performance of all three methods decreases. MetaSparseKmeans
(both EW and UW) outperforms individual analysis. Figure 5(b) shows the performance
of three methods when the subtype predictive gene fold change in the largest study f
varies: f = 0.8, 0.9 ∼ 2 (error bars represent mean ± standard error). When the largest
study has stronger signal f > 1, performance of MetaSparseKmeans-UW is better than
MetaSparseKmeans-EW. When the largest study has weaker signal f < 1, performance of
MetaSparseKmeans-EW is better than MetaSparseKmeans-UW. Figure 5(c) shows a third
simulation when the fold change of the confounding impacted genes in the largest study
varies: f = 0.8, 0.9 ∼ 2 (error bars represent mean ± standard error). When the largest
study has strong confounding effect (i.e. heterogeneous compared to other studies) f > 1,
MetaSparseKmeans-UW has worse performance than MetaSparseKmeans-EW and can be
even worse than individual study clustering. When the studies are more homogeneous f < 1,
performance of MetaSparseKmeans-UW is superior.
33
(a) Vary biological variance
(b) Vary subtype signal in the largest study (c) Vary confounding effect in the largest study
Figure 5: Simulation result comparing MetaSparseKmeans.
Simulation result comparing MetaSparseKmeans(EW), MetaSparseKmeans (UW) and
sparse K-means under different scenarios. Figure 5(a): varying biological variance. Fig-
ure 5(b): varying subtype predictive gene intensity in the first study with the largest sample
size. Figure 5(c): varying confounding impacted gene intensity in the first study with the
largest sample size.
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Table 2: Leukemia dataset information
Study Name Verhaak at el. Balgobind at el. Kohlmann at el.
Number of probes 48,788 48,788 48,788
Number of patients 89 74 105
True class label ? (33, 21, 35) (27, 19, 28) (28, 37, 40)
Data range [4.907, 14.159] [3.169, 15.132] [0, 1]
Mean intensity 6.163 6.093 0.309
Standard deviation 1.543 1.334 0.196
Platform Affymetrix human genome u133 plus 2.0 array
?: true class labels are the number of samples for (inv(16), t(15:17), t(8,21))
2.4.2 Leukemia example
Table 2 shows a summary description of three Leukemia transcriptomic studies: Verhaak
(Verhaak et al., 2009), Balgobind (Balgobind et al., 2011), Kohlmann (Kohlmann et al.,
2008). We only considered samples from acute myeloid leukemia (AML) with subtype
inv(16)(inversions in chromosome 16), t(15;17)(translocations between chromosome 15 and
17), t(8;21)(translocations between chromosome 8 and 21). These three gene-translocation
AML subtypes have been well-studied with different survival, treatment response and prog-
nosis outcomes. We treat these class labels as the underlying truth to evaluate the clustering
performance. The expression data for Verhaak, Balgobind ranged from around [3.169, 15.132]
while Kohlmann ranged in [0, 1]. All the datasets were downloaded directly from NCBI GEO
website. Originally there were 54,613 probe sets and we filtered out probes with 0 standard
deviation in any study. In the end 48,788 probes were remained matched across studies.
Three gene expression matrices with sample size 89, 74 and 105 were used as input data for
disease subtype discovery.
To compare the performance between MetaSparseKmeans and single sparse K-means,
we chose µ such that the number of selected probe sets was around 200-300 in each method.
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Table 3: Comparison between MetaSparseKmeans and sparse K-means on Leukemia dataset
MSKM Verhaak Balgobind Kohlmann
µ 12 10 10 10
Number of selected probes 245 266 257 218
ARI 0.97/1/0.95 0.97 0.41 0.95
Figure 6(a)-6(c) show heatmap of clustering results from each single study sparse K-means.
Each study generated three disease subtypes using different intrinsic gene sets, making it
difficult to classify future patients with a unified classification rule. Figure 6(d)-6(f) demon-
strate heatmap from MetaSparseKmeans clustering using 245 probe sets. We not only
obtained a common intrinsic gene set, but also observed clear consistent patterns of the
three disease subtypes across the three studies. Table 3 shows the ARI of each cluster-
ing result with the underlying leukemia subtype truth. Single study analysis in Verhaak
and Kohlmann produced almost perfect clustering (ARI = 0.97 and 0.95) while Balgobind
gave a poor ARI = 0.41. The MetaSparseKmeans generated improved ARIs in each study
(ARI = 0.97, 1 and 0.95).
2.4.3 Breast cancer example
2.4.3.1 Clustering result and survival association As shown in the motivating ex-
ample in Figure 2(a)-2(c), single study sparse K-means generated different sets of intrinsic
genes. MetaSparseKmeans obtained 203 common intrinsic genes to cluster the patients into
five disease subtypes with consistent expression pattern across studies. Since the underlying
true cancer subtypes are not available in this example, we applied the models from each
method to classify an independent testing cohort METABRIC (Curtis et al., 2012), which
contained 1,981 samples from Illumina HT12 arrays. This serves the purpose of extend-
ing the training model to a validating dataset. Figure 7(a) shows the subtype prediction
patterns from MetaSparseKmeans method. We can clearly see that the resulting expres-
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(a) Verhaak at el. (266 probes) (b) Balgobind at el. (257 probes) (c) Kohlmann at el. (218 probes)
(d) Verhaak at el. (245 probes) (e) Balgobind at el. (245
probes)
(f) Kohlmann at el. (245
probes)
Figure 6: Leukemia results after MetaSparseKmeans.
The three figures on top are heatmaps of Leukemia dataset after sparse K-means. The three
figures on bottom are results from MetaSparseKmeans.
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Table 4: Survival analysis in METABRIC
Model # of Samples # of selected genes p value
Meta(TCGA+Wang+Desmedt) 533+260+164 203(194) 3.79× 10−25
TCGA 533 239(233) 1.46× 10−19
Wang 260 220(214) 3.31× 10−14
Desmedt 164 197(193) 7.81× 10−14
PAM50 50 1.01× 10−20
Classification models trained in each single study and combined meta-framework are applied
to METABRIC. P-value of survival differences of identified subgroups were evaluated based
on log-rank test. The previously published PAM50 model was also compared. The number
in () indicates the actual number of genes used in the prediction model since a few genes
were not observed in the METABRIC array platform.
sion patterns are consistent with those from three training studies in Figure 2(d)-2(f). The
Kaplan-Meier survival curves of the five disease subtypes are well-separated with p-value
3.79 × 10−25 from log-rank test (Figure 7(b)). The survival separation demonstrates high
potential of clinical utility of the discovered disease subtypes. Note that although only 194
out of 203 genes appeared in the METABRIC dataset, those genes still had enough power to
separate the subtypes. Table 4 shows log-rank p-value of survival separation from each in-
dividual sparse K-means classification and PAM50. MetaSparseKmeans generated the best
survival separation of the subtypes. PAM50 is currently the most well-accepted transcrip-
tomic subtype definition of breast cancer. We have further compared the clustering results
from MetaSparseKmeans and PAM50 in the Appendix and Supplement Table 12
2.4.3.2 Pathway Enrichment In order to evaluate whether the genes obtained from
each model are biologically meaningful, pathway enrichment analysis was perform using
Fisher’s exact tests by testing association of selected intrinsic genes and genes in a par-
ticular pathway. We applied the BioCarta Database obtained from MSigDB (http://www.
broadinstitute.org/gsea/msigdb/collections.jsp#C2). This database contains 217 cu-
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(a) Heatmap of METABRIC based on 194 genes
from MetaSparseKmeans.
(b) Survival curves of the 5 subtypes from
MetaSparseKmeans validation. The color is cor-
responding to the subtype color in the heatmap.
Figure 7: Clinical result of METABRIC dataset
rated cancer related pathways and is particularly suited to evaluate the breast cancer exam-
ple. Figure 8 shows the jitter plot pathway enrichment q-values at log-scale (base 10). The
horizontal solid line corresponds to the q = 0.05 significance level threshold. The pathway
enrichment result from MetaSparseKmeans yielded more significant pathways than the in-
dividual models(7 significant pathway in MetaSparseKmeans versus 1 in individual sparse
K-means). All 8 significant pathways are listed in Table 5.
2.4.3.3 Accuracy and stability analysis We have performed additional subsampling
evaluation on breast cancers studies to evaluate the accuracy and stability of
MetaSparseKmeans compared to single study analysis. For accuracy, since TCGA had larger
sample size than the other two studies, we randomly subsampled 50%, 60%, 70%, 80%, 90%
of samples in TCGA for evaluation. Sparse K-means was applied to the whole TCGA data
(n=533) without considering Wang and Desmedt to generate sample clustering CTCGA,all and
this result was treated as a pseudo-gold standard. Sparse K-means was then similarly ap-
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Table 5: Eight significant BIOCARTA pathways.
Pathway name MetaSparseKmeans TCGA Wang Desmedt
BIOCARTA SRCRPTP PATHWAY ?0.0255 1 1 1
BIOCARTA MCM PATHWAY ?6.47× 10−6 1 1 1
BIOCARTA G1 PATHWAY ?0.0427 1 1 1
BIOCARTA G2 PATHWAY ?0.0367 1 1 1
BIOCARTA P27 PATHWAY ?0.0472 1 1 1
BIOCARTA RANMS PATHWAY ?0.0229 1 1 1
BIOCARTA PTC1 PATHWAY ?0.0287 1 1 1
BIOCARTA HER2 PATHWAY 0.149 0.170 ?0.0078 0.0817
The p-values were obtained using Fisher’s exact tests based on selected genes from
MetaSparseKmeans or individual study clustering and Benjamini-Hochberg correction (Ben-
jamini and Hochberg, 1995) was applied to generate q-values in the table. ?: q-value smaller
than 0.05 cutoff.
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Figure 8: Pathway enrichment result from four different models (Meta, TCGA, Wang,
Desmedt).
Clustering from meta-analysis identified intrinsic genes more associated to cancer related
pathways.
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plied to 100 independently subsampled p%(p = 50, 60, 70, 80, 90) TCGA dataset to generate
clustering result C
(b)
TCGA,p% (1 ≤ b ≤ 100). The adjusted Rand index (ARI) was calculated
between C
(b)
TCGA,p% and CTCGA,all and the trajectories with error bar (standard error) are
shown in Figure 9(a) (blue). Similar analysis was performed for MetaSparseKmeans when
the TCGA subtype clustering results were combined with Wang and Desmedt for cluster-
ing and the ARI results were shown in red. In this analysis, we used the large sample size
of TCGA data to generate the subtype clustering result and treated it as a pseudo-gold
standard. The data subsampling represented the situation when sample size was not large
and the ARI value represented an indirect evidence of the clustering accuracy. Figure 9(a)
demonstrates a clearly better accuracy for MetaSparseKmeans than single study sparse K-
means and the increased power evidently comes from the incorporated information from the
other two studies, Wang and Desmedt.
For stability, we performed similar subsampling in TCGA data as before. But instead
of comparing to the whole data clustering results, we restricted to all pair-wise comparison
of subsampled data. For a given p% subsampling rate, B (B = 100) TCGA subsampled
data were generated and sparse K-means were applied to each subsampled dataset. ARIs
were calculated for each pair-wise comparison that generated C1002 = 4950 ARIs and the
trajectories with error bar (standard error) are shown in Figure 9(b) (blue). Similar analysis
for MetaSparseKmeans was performed where Wang and Desmedt were combined with sub-
sampled TCGA data in the subtype clustering (red in Figure 9(b)). The result showed that
MetaSparseKmeans generated more stable disease subtype assignments than single study
sparse K-means by incorporating information from the other two studies. Note that when
comparing two p% subsampled clustering results, only overlapped samples were considered
in the ARI calculation.
2.4.4 Computation time and matching accuracy
To evaluate computation time for the MetaSparseKmeans algorithm using different pattern
matching algorithms, we will use the simulation scenario in Section 3.4.1 with different S, K
and σ. We use two criteria to evaluate the accuracy for using different matching algorithms
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Table 6: Computing time for different matching methods
Algorithm S=3 S=5 S=15
Exhaustive 2.604 5.614 > 2.9× 104
K=3 Stepwise 2.854 5.290 18.024
MCMC 4.288 7.429 35.736
Exhaustive 15.616 > 2.9× 104 > 2.9× 104
K=5 Stepwise 8.738 13.951 39.273
MCMC 11.645 16.541 78.687
Computing time in minutes comparing different combination of S and K using a regular
desktop computer.
described in Section 2.3.2.2: percent of reaching global optimal based on Equation 2.3.4b,
and the resulting cluster agreement with the underlying truth using ARI. Table 6 shows
that stepwise and MCMC searching greatly reduced computing time for large S. Even in
a large meta-analysis of S = 15 and K = 5, computing time was at 39 and 79 minutes
without using any powerful machine or parallel programming. In Table 7, we fixed S = 3
and K = 3 and varied biological variance σ = 2, 6 and did 100 simulations for each σ.
On the left, the performance of matching score is evaluated by comparing with exhaustive
matching score. We observed that stepwise matching sometime will deviate from the optimal
matching, but MCMC (with stepwise initial) can increase the chance to the best matching.
On the right, we evaluated the final cluster agreement. We observed that all of the three
methods would achieved similar performance. The result demonstrates that MCMC achieves
the best balance between computing load and optimization performance. Besides, in our real
data examples, all three matching algorithms will yield the same clustering result.
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Table 7: Accuracy for different matching methods
% of optimal accuracy
Variance σ = 2 σ = 6 σ = 2 σ = 6
Exhaustive 100% 100% 0.829± 0.031 0.020± 0.002
Stepwise 93.3% 92.8% 0.828± 0.031 0.020± 0.002
MCMC 100% 100% 0.828± 0.031 0.020± 0.002
Performance comparing with the best matching score (percentage of agreement with optimal
matching) and clustering accuracy by ARI (mean estimate± standard error) under different
biological variances (σ = 2 and σ = 6).
(a) accuracy (b) robustness
Figure 9: Accuracy comparison of MetaSparseKmeans and sparse K-means.
Figure 9(a) compares the accuracy of MetaSparseKmeans and sparse K-means. For sparse
K-means we used the TCGA data (n=533) only and for MetaSparseKmeans we combined
TCGA, Wang and Desmedt. At each sub-sampling point, ARI was calculated 100 times and
averaged. Figure 9(b) compares the stability of MetaSparseKmeans and sparse K-means.
At each sub-sampling point, ARI was calculated 4950 times and averaged.
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2.5 DISCUSSION
Disease phenotyping and subtype discovery have received increasing attention since high-
throughput experimental data have become more and more affordable and prevalent. In the
literature, such a modeling is usually performed in a single study and attempts have been
made to validate in other studies. As more and more studies of the same disease are available,
combining multiple studies for simultaneous subtype clustering is an appealing approach
to identify a common set of intrinsic genes and a common model of subtype definition
for future prediction. In this chapter, we developed a MetaSparseKmeans framework that
can achieve this goal. Simulations and applications to leukemia datasets and breast cancer
datasets demonstrated improved performance by meta-analysis. We demonstrated a superior
accuracy and stability of MetaSparseKmeans compared to individual analysis counterpart
in the breast cancer example. We also performed an validation on a large independent
METABRIC study which evaluated its potential clinical significance by survival analysis
and demonstrated the better pathway association of the identified intrinsic genes with cancer
related pathways.
Although MetaSparseKmeans was mainly applied to transcriptomic studies in this chap-
ter, it can also be applied to other high-throughput omics data such as methylation, copy
number variation, miRNA and proteomics. There are a few potential extensions of
MetaSparseKmeans. First of all, the feature selection in sparse K-means ignores prior
knowledge or dependence structure between features. For example, if features contain both
gene expression and methylation, the inter-relationship between multi-omics data may be
modeled to improve the analysis and interpretation. Secondly, the gap statistic usually leads
to a candidate region with near optimal µ and we selected µ corresponding to less number
of features. One may design a penalized gap statistics for which µ could be automatically
selected. Thirdly, disease-related genes or pathways may be available in well-studied diseases.
Incorporating these prior biological information may generate more biologically relevant
results and is a future direction. Finally, subtypes identified by MetaSparseKmeans do not
necessarily guarantee association with clinical outcome (e.g. survival, tumor stage, tumor
grade etc). It is possible that less obvious subtypes with important clinical association may
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be masked by strong subtypes with no clinical importance. A guided clustering approach
incorporating prior clinical information may help identify clinically relevant disease subtypes.
MetaSparseKmeans inherits fast computation from K-means algorithms. The stepwise
search algorithm and simulated annealing also provide a viable solution to the large searching
space of cluster matching when the number of studies is large. In the breast cancer example
(K = 5 and S = 3), MetaSparseKmeans took only about 8 minutes for exhaustive search
using a regular laptop (CPU 2GHz and 4GB RAM). An R package MetaSparseKmeans is
available to perform the analysis.
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3.0 INTEGRATIVE SPARSE KMEANS
3.1 INTRODUCTION
In section 1.2, we introduced the background for disease subtype discovery via transcrip-
tomic data. In section 3.1, we introduced the background of horizontal meta-analysis for 
disease subtype discovery via combining multiple transcriptomic studies. Over the years 
large amount of omics data are accumulated in public databases and depositories, vertical 
integrative analysis is appealing since we are able to draw robust conclusion by taking into 
account the regulatory relationships between different levels of omics data. Omics integrative 
analysis has been found successful in many applications: (e.g. breast cancer (Koboldt et al., 
2012), stomach cancer (Bass et al., 2014)). On the other hand, tremendous amount of bio-
logical information has been accumulated in public databases. Proper usage of these prior 
information (e.g. pathway information and miRNA targeting gene database) can greatly 
guide the modeling of omics integrative analysis.
In this chapter, we focus on vertical omics integrative analysis for disease subtype discov-
ery. Several methods for this purpose have been proposed in the literature. Lock and Dunson 
(2013) fitted a finite Dirichlet mixture model to perform Bayesian consensus clustering that 
allows common clustering across omics types as well as omics-type-specific clustering. The 
model, however, does not perform proper feature selection and thus is not suitable for high-
dimensional omics data. Shen et al. (2009) proposed a latent variable factor model (namely 
iCluster) to cluster cancer samples by integrating multi-omics data. The method does not 
incorporate prior biological knowledge and requires extensive computing due to EM algo-
rithm with large matrix operation. We will use the popular iCluster method as the baseline 
method to compare in this chapter. The content of this chapter is accepted by the Annals
of Applied Statistics (Huo and Tseng, 2017).
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The central question we ask in this Chapter is: “Can we identify cancer subtypes by 
simultaneously integrating multi-level omics datasets and/or utilizing existing biological 
knowledge to increase accuracy and interpretation?” Several statistical challenges will arise 
when we attempt to achieve this goal: (1) If multi-level omics data are available for a given 
patient cohort, what kind of method is effective to achieve robust and accurate disease sub-
type detection via integrating multi-omics data? (2) Since only a small subset of intrinsic 
omics features are relevant to the disease subtype characterization, how can we perform 
effective feature selection in the high-dimensional integrative analysis? (3) With the rich 
biological information (e.g. targeted genes of each miRNA or potential cis-acting regulatory 
mechanism between copy number variation, methylation and gene expression), how can we 
fully utilize the prior information to guide feature selection and clustering? In this chapter, we 
propose an integrative sparse K-means (IS-Kmeans) (Huo and Tseng, 2017) approach by 
extending the sparse K-means algorithm with overlapping group lasso technique to accom-
modate the three goals described above. The lasso penalty in the sparse K-means method 
allows effective feature selection for clustering. In the literature, (non-overlapping) group lasso 
(Yuan and Lin, 2006) has been developed in a regression setting to encourage features of the 
same group to be selected or excluded together. The approach, however, has two major 
drawbacks: (1) it does not allow sparsity within groups (i.e. a group of features are either all 
selected or all excluded), and (2) the penalty function does not allow overlapping groups. For 
the first issue, Simon et al. (2013) proposed a sparse group lasso with both an l1 lasso penalty 
and a group lasso penalty to allow sparsity within groups while the approach does not allow 
overlapping groups. For the latter issue, overlapping group information from biological 
knowledge is frequently encountered in many applications. In genomic application, for 
example, the targeted genes of two miRNAs are often overlapped or two pathways may 
contain overlapping genes. Jacob et al. (2009) proposed a duplication technique to allow 
overlapping groups in regression setting while the approach does not allow sparsity within 
groups. In this chapter, we attempt to simultaneously overcome both aforementioned diffi-
culties in a clustering setting, which brings optimization challenges beyond the duplication 
technique by Jacob et al. (2009) and the sparse group lasso optimization by Simon et al.
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(2013). In our proposed IS-Kmeans method, we will develop a novel reformulation of l1 lasso
penalty and overlapping group lasso penalty so that a fast optimization technique using al-
ternating direction method of multiplier (ADMM) (Boyd et al., 2011) can be applied (see
Section 3.3.3.1).
The rest of the chapter is structured as following. Section 3.2 gives a motivating example.
Section 3.3 establishes the method and optimization procedure. Section 3.4.1-3.4.3 compre-
hensively compares the proposed method with the popular iCluster method using simulation
and two breast cancer applications on multi-level omics data. Section 3.4.4 provides another
type of IS-Kmeans application of pathway-guided clustering on single transcriptomic study.
Section 3.5 includes final conclusion and discussion.
3.2 MOTIVATING EXAMPLE
Figure 10A shows a clustering result using single study sparse K-means (detailed algorithm
see Section 1.3.3.2) on the mRNA, methylation and copy number variation (CNV) datasets
separately from 770 samples in TCGA. As expected, they generate very different disease
subtyping without regulatory inference across mRNA, methylation and CNV. In this exam-
ple, single study sparse K-means fails to consider that different omics features belonging to
the same genes are likely to contain cis-acting regulatory mechanisms related to the disease
subtypes. Figure 10B combines the three datasets to perform IS-Kmeans. The IS-Kmeans
generates a single disease subtyping and takes into account of the prior regulatory knowledge
between mRNA, methylation and CNV. The prior knowledge can also be pathway database
(e.g. KEGG, BioCarta and Reactome) or knowledge of miRNA targets prediction databases
(e.g. PicTar, TargetScan, DIANA-microT, miRanda, rna22 and PITA) (Witkos et al., 2011;
Fan and Kurgan, 2015). Incorporating such prior information of feature grouping increases
statistical power and interpretation. Figure 10C shows a simple example of such group prior
knowledge. Pathway J1 includes mRNA1, mRNA2, mRNA3 and mRNA6 while pathway
J2 includes mRNA3, mRNA4, mRNA5 and mRNA7. Note that mRNA3 appears in both
pathway J1 and J2, which requires our algorithm to allow overlapping groups. Our goal is
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to develop a sparse clustering algorithm integrating multi-level omics datasets and the afore-
mentioned prior regulatory knowledge by overlapping group lasso. The algorithm is also
suitable for single omics dataset with incorporating prior overlapping pathway information
(see the leukemia examples in Section 3.4.4).
3.3 METHOD
3.3.1 Integrative Sparse K-means (IS-Kmeans)
We have introduced K-means and sparse K-means in Section 1.3.3.2. We extend the sparse
K-means objective function to group structured sparse K-means. Here we consider J to be
the total number of features combing all levels of omics datasets. In order to make features
of different omics data types on the same scale and comparable, we normalized BCSSj by
TSSj and denote
Rj(C) =
BCSSj(C)
TSSj
We put the overlapping group lasso penalty term Ω(z) in the objective function.
min
C,z
−
J∑
j=1
zjRj(C) + γα‖z‖1 + γ(1− α)Ω(z) (3.3.1)
subject to ‖z‖2 ≤ 1, zj ≥ 0,
where γ is the penalty tuning parameter controlling the numbers of non-zero features, α ∈
[0, 1] is a term controlling the balance between individual feature penalty and group feature
penalty. If α = 1, there is no group feature penalty term and the objective function is
equivalent to sparse K-means objective function after standardizing each feature. If α = 0,
there is no individual feature penalty and only group feature penalty exists. The overlapping
group lasso penalty term is defined as
Ω(z) =
∑
1≤g≤G0
wg‖mg ◦ z‖2,
where G0 is the number of (possibly overlapping) feature groups from prior biological knowl-
edge, wg ∈ R is the group weight coefficient for group g, mg = (mg1, . . . ,mgJ) is the design
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vector of the gth feature group and ◦ represents Hadamard product. The design of wg and mg 
is discussed in Section 3.3.2. Note that features with no group information are also treated
as a group by itself (a group only contains a feature); such a design is to avoid bias towards
a feature with no group information by receiving no penalization. The feature groups can
either come from existing biological databases (e.g. pathway or miRNA target database), or
from basic biological cis-regulatory knowledge (CNV and methylation features in the neigh-
borhood of a nearby gene region). The first term in Equation 3.3.1 encourages large weights
for features with strong clustering separability. The second term is an l1 norm lasso penalty
to encourage sparsity. Finally, Ω(z) serves as overlapping group lasso to encourage features
in the prior knowledge groups to be selected simultaneously (or discarded together). The
intuition of group lasso is that if we transform the Lagrange form of Ω(z) to its constraint
form, it becomes an elliptic constraint and features of the same group are preferred to be
selected together (Yuan and Lin, 2006; Jacob et al., 2009). The combination of l1 norm lasso
penalty and overlapping group lasso penalty Ω(z) serves to achieve a sparse feature selection
and also encourages (but does not force) features of the same group to be selected together.
Remark. Since different types of omics datasets may have different value ranges and dis-
tributions, additional normalization may be needed in the preprocessing. For example, the
commonly-used beta values from methy-seq (defined as “methylation counts”/“total counts”)
represent the proportions of methylation and range between 0 and 1. A logit transformation
to so-called M-values is closer to Gaussian distribution and is more suitable to integrate
with other omics data. Similarly, log-transformation of expression intensities from microar-
ray, log-transformation of RPKM/TPM (summarized expression values) from RNA-seq and
log-ratio values of CNV values from SNP arrays have been shown to be roughly Gaussian
distributed and are proper for multi-omics integration. Another possibility is by replacing
Euclidean distance to an appropriate distance measurement (e.g. Gower’s distance for bi-
nary categorical and ordinal data, and Bray-Curtis dissimilarity for count data). Under this
scenario, Equation 3.3.1 remains valid under such modification and we only need to incorpo-
rate partition around medoids (PAM) (Kaufman and Rousseeuw, 1987) instead of K-means
in the optimization procedure in Section 3.3.3.1. However, heterogeneity of different distance
measurement may require extra different sparsity penalties and this is beyond consideration
in this dissertation.
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3.3.2 Design of overlapping group lasso penalty
In this section, we discuss and justify the design of overlapping group lasso penalty for 
wg and mg. We denote by Jg as the collection of features in group g (1 ≤ g ≤ G0) and
define frequency of feature j appearing in different groups: h(j) =
∑
1≤g≤G0 I{j ∈ Jg}. We
also define the intrinsic feature set I (i.e. features that contribute to the underlying true
sample clustering) and the non-intrinsic feature set I¯. We first state an “Unbiased Feature
Selection” principle under a simplified situation:
Definition 3.3.1 (“Unbiased Feature Selection” principle). Suppose equal separation ability
in all intrinsic features I = {j : Rj = R > 0} and no separation ability in non-intrinsic
features I¯ = {j : Rj = 0} under the true clustering label. The proposed overlapping group
lasso design (wg and mg) is said to satisfy the “Unbiased Feature Selection” principle if
under Equation 3.3.1, it generates equal weights zj = 1/
√|I| for j ∈ I and zj = 0 for j ∈ I¯
given any prior knowledge of feature groups Jg, 1 ≤ g ≤ G0.
The theorem below states an overlapping group lasso penalty design that satisfies “Un-
biased Feature Selection” principle when all features are intrinsic features (i.e. I¯ = φ).
Theorem 3.3.1. Consider Ω(z) =
∑
1≤g≤G0 wg‖mg ◦z‖2 and mg = (mg1, . . . ,mgj, . . . ,mgJ)
in Equation 3.3.1. Suppose equal separation ability for all features R1 = . . . = RJ = R (I¯ =
φ) and further assume R > γ. The design of mgj = I{j ∈ Jg}/
√
h(j), wg =
√∑
j∈Jg 1/h(j)
satisfies the “Unbiased Feature Selection” principle such that optimum solution of z from
Equation 3.3.1 generates zj = 1/
√
J , ∀j.
Theorem 3.3.1 gives a design of overlapping group lasso penalty such that given equal
separation ability for all features, the feature selection is not biased by the prior group
knowledge. When all the groups are non-overlapping, h(j) = 1,∀j, then
Ω(z) =
∑
0≤g≤G0
(√
|Jg|
√∑
j∈Jg
z2j
)
,
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where |Jg| is number of features in group Jg, which is the non-overlapping group lasso
penalty (Yuan and Lin, 2006). However, this weight design
(
wg =
√∑
j∈Jg 1/h(j)
)
is not
applicable when the underlying intrinsic feature set is sparse (i.e. I¯ 6= φ). If there are
many non-intrinsic features inside group g, the intrinsic features in group g is over penalized
since wg is inflated by the contribution of non-intrinsic features. Therefore, we propose
the following overlapping group lasso penalty and show that the design satisfies “Unbiased
Feature Selection” principle when intrinsic feature set is sparse.
mgj = I{j ∈ Jg}/
√
h(j) (3.3.2)
wg =
√ ∑
j∈(Jg∩I)
1/h(j)
Theorem 3.3.2. Suppose the intrinsic feature set I = {j : Rj = R > 0} and the non-
intrinsic feature set I¯ = {j : Rj = 0}. We further assume R > γ. The overlapping group
lasso penalty in Equation 3.3.2 satisfies the “Unbiased Feature Selection” principle such that
the optimum solution of z from Equation 3.3.1 is zj = 1/
√|I| for j ∈ I and zj = 0 for
j ∈ I¯.
Note that we take into account both the non-intrinsic features and the intrinsic features
in the penalty design in Equation 3.3.2. Only intrinsic features contribute to the group
weight coefficient wg. The design vector mg remains the same as non-overlapping group
lasso. In practice, the intrinsic feature set I is unknown. We follow the coefficient design
of adaptive lasso (Zou, 2006) and adaptive group lasso (Huang et al., 2010), which have
been discussed in the literature and they maintain consistency property under certain mild
conditions. Specifically, we set α = 1 in Equation 3.3.1 where only individual feature
penalty is considered and use the solution zˆ to define estimated intrinsic feature set Iˆ =
{j : zˆj > 0} and non-intrinsic feature set ˆ¯I = {j : zˆj = 0} for Equation 3.3.2. In the
example of Figure 10C, suppose all 7 features are intrinsic genes. Pathway J1 contains
mRNA1, mRNA2, mRNA3 and mRNA6, reflecting prior knowledge from pathway databases.
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Similarly, group for pathway J2 contains mRNA3, mRNA4, mRNA5 and mRNA7. As a
result, m1 = (1, 1, 1/2, 0, 0, 1, 0) and m2 = (0, 0, 1/2, 1, 1, 0, 1) and
Ω(z) =
√
1 + 1 + 1/2 + 1
√
z21 + z
2
2 + 1/2× z23 + z26+√
1/2 + 1 + 1 + 1
√
1/2× z23 + z24 + z25 + z27 .
Note that in our example mRNA3 is shared by pathway groups J1 and J2, representing
overlapping group lasso penalty.
3.3.3 Optimization
In this section, we discuss major issues for optimization of Equation 3.3.1. Firstly we intro-
duce transformation of Equation 3.3.1 such that l1 norm penalty can be absorbed in l2 norm
group penalty. Secondly we introduce the optimization procedure for the proposed objective
function. Thirdly, we discuss how to use ADMM to optimize the weight term, which is
critical and a difficult problem since it involves both the l1 norm penalty and overlapping
group lasso penalty. Lastly, we discuss the stopping rule for the optimization.
3.3.3.1 Reformulation and iterative optimization We use the fact that γα‖z‖1 can
be re-written as γα‖z‖1 = γα
∑J
j=1 ‖zj‖2 and zj = (0, . . . , zj, . . . , 0)> with only the jth
element non-zero. In other words, the l1 norm penalty of a single feature can be deemed
as group penalty with only one feature within a group. Therefore we can rewrite objective
function Equation 3.3.1 as
min
C,z
−
J∑
j=1
zjRj(C) +
J∑
j=1
‖γαφj ◦ z‖2 +
∑
0≤g≤G0
‖γ(1− α)mg ◦ z‖2 (3.3.3)
s.t. ‖z‖2 ≤ 1, zj ≥ 0, where φj = (φj1, . . . ,φjJ), φj i = 1 if j = i and φj i = 0 if j 6= i. We
combine J and G0 groups and the combined groups are of size G = J + G0. Define
βg =
γαφj , if 1 ≤ g ≤ J,γ(1− α)mg, if J + 1 ≤ g ≤ G.
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Therefore we can rewrite objective function Equation 3.3.3 as
min−R(C)>z +
∑
1≤g≤G
‖βg ◦ z‖2 (3.3.4)
subject to ‖z‖2 ≤ 1, zj ≥ 0,
where R(C) = (R1(C), . . . , RJ(C))
>. The optimization procedure are outlined below:
1. Initialize weight z using the original sparse K-means method without the group lasso
term.
2. Given weight z, use weighted K-means to update cluster labels C (R is the normalized
WCSS so minimizing −R(C)>z is essentially weighed K-means). This is a non-convex
problem so multiple random starts are recommended to alleviate local minimum problem.
3. Given the cluster label C, R is fixed so optimizing the objective function is a convex
problem with respect to solving weight z. We use ADMM in the next subsection to
update weight z.
4. Iterate 2 and 3 until converge.
The detailed algorithm for Step 3 is outlined in Section 3.3.3.2 and the stopping rules of
Step 3 and Step 4 are described in Section 3.3.3.3.
3.3.3.2 Update weight using ADMM Alternating direction method of multiplier
(ADMM) (Boyd et al., 2011) is ideal for solving the optimization in Equation 3.3.4. We
introduce an auxiliary variable xg and write down the augmented Lagrange.
min−R(C)>z +
∑
1≤g≤G
‖xg‖2 +
∑
1≤g≤G
{y>g (xg − βg ◦ z) +
ρ
2
‖xg − βg ◦ z‖22} (3.3.5)
s.t. ‖z‖2 ≤ 1, zj ≥ 0, and xg = βg ◦z. This problem (Equation 3.3.5) is clearly equivalent to
the original objective function (Equation 3.3.4), since for any feasible z the terms added to
the objective is zero. ρ is the augmented Lagrange parameter which will be discussed in more
detail in Section 3.3.3.4. Here the augmented Lagrange is minimized jointly with respect to
the two primal variables xg, z and the dual variable yg. In ADMM, xg, z and yg are updated
in an alternating or sequential fashion (Boyd et al., 2011) and thus the optimization problem
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can be decomposed into three parts. Given (xg, z and yg), the new iteration of (x
+
g , z
+ and
y+g ) in Equation 3.3.5 is updated as following.

x+g = arg minxg ‖xg‖2 + y>g xg + ρ2‖xg − βg ◦ z‖22
z+ = arg minz−
∑
zjRj −
∑
1≤g≤G y
>
g (βg ◦ z) + ρ2‖x+g − βg ◦ z‖22
subject to ‖z‖2 ≤ 1, zj ≥ 0.
y+g = yg + ρ(x
+
g − βg ◦ z+)
Where the updating equation of x+g and z
+ are derived from Equation 3.3.5 and the the
updating equation of y+g is imbedded in ADMM procedure (Boyd et al., 2011). We can
derive close form solution for xg part and z part by Karush-Kuhn-Tucker (KKT) condition.
Details are given in the Appendix.
1. Define ag = βg ◦ z− ygρ , we have x+g = (1− 1ρ‖ag‖2 )+ag, where (·)+ = max(0, ·).
2. Define bj =
∑
1≤g≤G ρβ
2
gj and cj =
∑
1≤g≤G
(
ρx+gj + ygj
) ◦ βgj, where
βg = (βg1,βg2, . . . ,βgJ)
>, xg = (xg1,xg2, . . . ,xgJ)> and yg = (yg1,yg2, . . . ,ygJ)>. The
solution is given as following: we define fj(u) = (
Rj+cj
bj+2u
)+. If
∑
j fj(u)
2 < 1, z+j = fj(0)
∀j. Otherwise z+j = fj(u) ∀j and u is selected s.t. ‖z+‖2 = 1.
3.3.3.3 Stopping rules We have two algorithms which require stopping rules. For
ADMM in the optimization of Step 3, the primal residual of group g in ADMM iteration t
is: rtg = x
t
g − βg ◦ zt, and the l2 norm of primal residual is rt =
√∑
g ‖rtg‖22. The l2 norm
of dual residual is: vt =
√∑
g ‖βg ◦ (zt − zt−1)‖22. We set our ADMM stopping criteria
such that simultaneously rt < 10−10 and vt < 10−10. For convergence of IS-Kmeans, we
iterate weighted K-means (Step 2) and updating weight by ADMM (Step 3) until converge.
(i.e.
∑J
j=1 |z(c)j −z(c−1)j |∑J
j=1 |z(c−1)j |
< 10−4), where z(c)j represents the zj estimate in the c
th iteration of the
IS-Kmeans algorithm.
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3.3.3.4 augmented Lagrangian parameter ρ Augmented Lagrangian parameter ρ
controls the convergence of ADMM. In fact, large value of ρ will lead to small primal residual
by placing a large penalty on violations of primal feasibility. And conversely, small value of ρ
tend to produce small dual residual, but it will result in a large primal residual by reducing
the penalty on primal feasibility (Boyd et al., 2011). An adaptive scheme of varying ρ to
balance the primal and dual residual has been proposed (He et al., 2000; Wang and Liao,
2001) which greatly accelerates ADMM convergence in practice.
ρt+1 =

τ incrρt, if ‖rt‖2 > η‖vt‖2,
ρt/τdecr, if ‖vt‖2 > η‖rt‖2,
ρt, otherwise.
We set η = 10 and τ incr = τdecr = 2. The intuition behind this scheme is to control both
primal and dual residuals for converging to zero simultaneously.
3.3.4 Select tuning parameters
In the objective function of IS-Kmeans, the number of clusters K is pre-specified. The issue
of estimating K has been widely discussed in the literature and has been well-recognized as a
difficult and data-dependent problem. (Milligan and Cooper, 1985; Kaufman and Rousseeuw,
2009). Here, we suggest the number of clusters to be estimated in each study separately
using conventional methods such as prediction strength (Tibshirani and Walther, 2005) or
gap statistics (Tibshirani et al., 2001) and jointly compared across studies (such that the
numbers of clusters are roughly the same for all studies) for a final decision before applying
integrative sparse K-means. Below we assume that a common K is pre-estimated for all
omics datasets.
Another important parameter to be determined is α, which controls the balance between
individual feature penalty and overlapping group penalty. According to the Equation 3.3.1,
α = 1 means we only emphasize on individual feature penalty and ignore overlapping group
penalty. In this case the IS-Kmeans is equivalent to sparse K-means. α = 0 means we only
emphasize overlapping group penalty and ignore individual feature penalty. Simon et al.
(2013) argued that there is no theoretically optimal selection for α because selection of α
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relates to multiple factors such as accuracy of prior group information and sparsity within
groups. In general, a large α (e.g. α = 0.95) is suitable when prior group information may
not be accurate or features within selected groups may be sparse. On the other hand, if we
expect mild sparsity within groups and high accuracy of prior group information, a small
α (e.g. α = 0.05) help select features by groups. In Section 3.4.1.2, we have performed
simulation of different level of prior group information accuracy (θ = 1 and θ = 0.2) and
found that α = 0.5 generates robust and high performance results in the sensitivity analysis.
As a result, we apply α = 0.5 throughout the chapter unless otherwise indicated.
The last tuning parameter is γ, which is the penalty coefficient. When γ is large, we
place large penalty on the objective function and end up with less selected features. When
γ is small, we put small penalty and will include more features. We follow and extend the
gap statistic procedure (Tibshirani et al., 2001) to estimate γ:
1. For each feature in each omics type, randomly permute the gene expression (permute
samples). This creates a permuted data set X(1). Repeat for B times to generate
X(1), X(2), . . . , X(B).
2. For each potential tuning parameter γ, compute the gap statistics as below.
Gap(γ) = O(γ)− 1
B
B∑
b=1
Ob(γ), (3.3.6)
where O(γ) = −∑Jj=1 z∗jRj(C∗) is from observed data, where z∗, C∗ are the minimizer of
the objective function in Equation 3.3.1 given γ. Ob(γ) is similar to O(γ) but generated
from permuted data X(b). Note that for
3. For a range of selections of γ, select γ∗ such that the gap statistics in Equation 3.3.6 is
minimized.
Figure 11 shows an example of a simulated dataset that will be discussed in Section 3.4.1. In
this example, we used α = 0.5 for IS-Kmeans and the minimum gap statistics corresponded
to 1778 genes, which is very close to the underlying truth 1800. The gap statistics for
α = 0.05, 0.95, 1 are plotted in Supplementary Figure 13 and they all provided adequate
γ estimation. In practice, calculating gap statistics from a chain of γ can be performed
efficiently by adopting warm start for adjacent γ’s. For example, after calculating O(γ1), the
58
resulting weights can be used as an initial value for the next nearby γ2 = γ1 + ∆ to calculate
O(γ2) in the optimization iteration for fast convergence.
3.4 RESULT
We evaluated integrative sparse K-means (IS-Kmeans) on simulation datasets in
Section 3.4.1, multiple-level omics applications using breast cancer TCGA (combining mRNA
expression, DNA methylation and copy number variation) and METABRIC (combining
mRNA expression and copy number variation) examples in Section 3.4.2 and 3.4.3, and
a pathway-guided single transcriptomic application in leukemia in Section 3.4.4. In the sim-
ulation, the underlying sample clusters and intrinsic feature set were known and we demon-
strated the better performance of IS-Kmeans compared to iCluster and sparse K-means
by cluster accuracy, feature selection and computing time. For the TCGA and METABRIC
application, the underlying true clustering and intrinsic feature set were not known. We eval-
uated the performance by clustering similarity using adjusted Rand index (ARI) (Hubert
and Arabie, 1985) with subtype definition by PAM50 (Parker et al., 2009), cis-regulatory
groups, survival difference between clusters and computing time. In the leukemia exam-
ples, the disease subtypes were defined by observable fusion gene aberration. We evaluated
the performance by clustering accuracy (ARI) and pathway enrichment analysis on selected
genes.
3.4.1 Simulation
3.4.1.1 Simulation setting To assess the performance of integrative sparse K-means
with different choices of α and compare to the original sparse K-means and iCluster, we
simulated K = 3 subtypes characterized by several groups of subtype predictive genes in
each of S = 2 omics datasets with 1 ≤ s ≤ S as the omics dataset index (e.g. s = 1 represents
gene expression and s = 2 represents DNA methylation). The prior group information was
imposed between groups of subtype predictive genes across omics datasets. These prior group
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information represent the possibility that a group of genes and DNA methylations might
be co-regulated. To best preserve the data nature of genomic studies, we also simulated
confounding variables, correlated gene structure and non-informative genes. Below is the
generative process:
(a) Subtype predictive genes (intrinsic feature set).
1. Denote by Nk is the number of subjects in subtype k(1 ≤ k ≤ 3). We simulate N1 ∼
POI(40), N2 ∼ POI(40), N3 ∼ POI(30) and the number of subjects is N =
∑
kNk.
Simulate S = 2 omics datasets, which share the samples and subtypes. Specifically, we
denote s = 1 to be the gene expression dataset and s = 2 to be the DNA methylation
dataset.
2. Simulate M = 30 feature modules (1 ≤ m ≤ M) for each omics dataset. Denote
nsm to be the number of features in omics dataset s and module m. For each module
in s = 1, sample n1m = 30 genes. For each module in s = 2, sample n2m = 30
methylations. Therefore, there will be of 1800 subtype predictive features among two
omics datasets.
3. Denote by µskm is the template gene expression (on log scale) of omics dataset s(1 ≤
s ≤ S), subtype k(1 ≤ k ≤ 3) and module m(1 ≤ m ≤ M). Simulate the template
gene expression µskm ∼ N(9, 22) with constrain maxp,q |µspm − µsqm| ≥ 1, where p, q
denote two subtypes. This part defines the subtype mean intensity for each module
in all omics datasets. Note that since in Equation 3.3.1 we used Rj =
BCSSj
TSSj
for
standardization, performance of the algorithm is robust to gene expression distribution
(e.g. the Gaussian assumption here).
4. In order to tune the signal of the template gene expression, we introduce a relative
effect size f > 0, such that µ
′
skm = (µskm −mink µskm)× f + mink µskm. If f = 1, we
don’t tune the signal. If f < 1, we decrease the signal and if f > 1, we amplify the
signal.
5. Add biological variation σ21 = 1 to the template gene expression and simulate X
′
skmi ∼
N(µ
′
skm, σ
2
1) for each module m, subject i(1 ≤ i ≤ Nk) of subtype k and omics dataset
s.
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6. Simulate the covariance matrix Σmks for genes in module m, subtype k and omics
dataset s, where 1 ≤ m ≤ M , 1 ≤ k ≤ 3 and 1 ≤ s ≤ S. First simulate Σ′mks ∼
W−1(Φ, 100), where Φ = 0.5Insm×nsm + 0.5Jnsm×nsm , W
−1 denotes the inverse Wishart
distribution, I is the identity matrix and J is the matrix with all elements equal 1.
Then Σmks is calculated by standardizing Σ
′
mks such that the diagonal elements are
all 1’s.
7. Simulate gene expression levels of genes in cluster m as (X1skmi, . . . , Xnsmskmi)
> ∼
MVN(X
′
skmi,Σmks), where 1 ≤ i ≤ Nks, 1 ≤ m ≤M , 1 ≤ k ≤ 3 and 1 ≤ s ≤ S.
(b) Non-informative genes.
1. Simulate 5000 non-informative genes denoted by g(1 ≤ g ≤ 5000) in each omics
dataset. First, we generate the mean template gene expression µsg ∼ N(9, 22). Then
we add biological variance σ22 = 1 to generate Xsgi ∼ N(µsg, σ22), 1 ≤ i ≤ Ns.
(c) Confounder impacted genes.
1. Simulate C = 2 confounding variables. In practice, confounding variables can be gen-
der, race, other demographic factors or disease stage etc. These will add heterogeneity
to each study to complicate disease subtype discovery. For each confounding variable
c(1 ≤ c ≤ C), we simulate R = 10 modules in each omics dataset. For each of these
modules rc(1 ≤ rc ≤ R), sample number of genes nrc = 30. Therefore, totally 600
confounder impacted genes are generated in each omics dataset. This procedure is
repeated in all S omics datasets.
2. For each omics dataset s(1 ≤ s ≤ S) and each confounding variable c, sample the
number of confounder subclass hsc = k. The N samples in omics dataset s will be
randomly divided into hsc subclasses.
3. Simulate confounding template gene expression µslrc ∼ N(9, 22) for confounder c,
gene module r, subclass l(1 ≤ l ≤ hsc) and omics dataset s. Similar to Step 5,
we add biological variation σ21 to the confounding template gene expression X
′
scrli ∼
N(µslrc, σ
2
1). Similar to Step 6 and 7, we simulate gene correlation structure within
modules of confounder impacted genes.
(d) Gene grouping information.
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1. We assume omics dataset s = 1 and s = 2 have prior group information on subtype
predictive gene modules. There are M = 30 modules in each omics dataset.
2. Suppose subtype predictive genes in the mth module of the first omics dataset are
grouped with methylation features in the second omics dataset (totally n1m + n2m =
30+30 = 60 features are in the same group). With probability 1−θ (0 ≤ θ ≤ 1), each
feature out of the 60 features will be randomly replaced by a confounder impacted
gene or non-informative gene. Note that the same replaced feature can appear in
multiple subtype predictive gene groups. We set θ = 1 and 0.2 to reflect 100%, 20%
accuracy of prior group information.
3.4.1.2 Simulation result For IS-Kmeans, the tuning parameter γ was selected by gap
statistics introduced in Section 3.3.4. Table 8 shows the result of gap statistics to select
the best γ in the simulation of α = 0.5, θ = 1. The smallest gap statistics was selected at
γ = 0.21 that correspond to selecting 1778 features, which was close to the underlying truth.
Similarly, gap statistics result for α = 1, 0.95, 0.05 are in the Supplementary Figure 13. For
simulation, we generated two scenarios with relative effect size f = 0.6 and f = 0.8. The
complete simulation result of f = 0.6 is shown in Table 8 and the result for f = 0.8 is in
the supplementary materials supplementary Table 13. For iCluster and sparse K-means,
we allowed them to choose their own optimum tuning parameters. Note that sparse K-
means was adopted to each individual omics datatype. We used ARI (Hubert and Arabie,
1985) and Jaccard index (Jaccard, 1901) to evaluate the clustering and feature selection
performance. ARI calculated similarity of the clustering result with the underlying true
clustering in simulation (range from -1 to 1 and 1 represents exact same partition compared
to the underlying truth). Jaccard index compared the similarity and diversity of two feature
sets, defined as the size of the intersection of two feature sets divided by the size of the union
of two feature sets (range from 0 to 1 and 1 represent identical feature sets compared to the
underlying truth). Clearly, IS-Kmeans outperformed iCluster and individual study sparse
K-means in terms of ARI and Jaccard index. IS-Kmeans and sparse K-means outperformed
iCluster in terms of computing time. Within IS-Kmeans, we compared feature selection
in terms of area under the curve (AUC) of ROC curve, which avoids the issue of tuning
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parameter selection. When θ = 1 (representing the grouping information is accurate), smaller
α (representing larger emphasize on grouping information) yielded better feature selection
performance in terms of AUC as expected. However, when θ = 0.2 (representing many errors
in the grouping information), smaller α yielded worse performance in terms of AUC. Note
that α = 0.5 gives robustness and performs well in the two extremes of θ = 1 and θ = 0.2.
In all applications below, we will apply α = 0.5 unless otherwise noted.
3.4.1.3 Data perturbation We also evaluated the stability of the algorithm against
data perturbation. Instead of Gaussian distribution in the data generative process, we
utilized heavy tailed t-distribution to generate the expression. In the simulation setting
Step a3, the template gene expression is simulated from a t-distribution with degree of
freedom 3, location parameter 9 and scale parameter 2. In Step a4, we set relative effect size
f = 0.6 and f = 0.8 respectively. In Step a5, X ′skmi is simulated from a t-distribution with
degree of freedom 3, location parameter µ′skm and scale parameter σ
2
1. The result for data
perturbation is in supplementary Table 16 and 17. The resulting message remains almost
the same as the conclusion in Section 3.4.1.2. Therefore, our proposed algorithm is robust
against non-Gaussian or heavy tail distributions.
3.4.2 Integrating TCGA Breast cancer mRNA, CNV and methylation
We downloaded TCGA breast cancer (BRCA) multi-level omics datasets from TCGA NIH
official website. TCGA BRCA gene expression (IlluminaHiSeq RNAseqV2) was downloaded
on 04/03/2015 with 20,531 genes and 1,095 subjects. TCGA BRCA DNA methylation
(Methylation450) was downloaded on 09/12/2015 with 485,577 probes and 894 subjects.
TCGA BRCA copy number variation (BI gistic2) was downloaded on 09/12/2015 with 24,776
genes and 1,079 subjects. There were 770 subjects with all these three omics data types.
Features (probes/genes) with any missing value were removed. For gene expression, we
transformed the FPKM value by log2(· + 1), where 1 is a pseudo-count to avoid undefined
log2(0), such that the transformed value was on continuous scale. For methylation, the
Methylation450 platform provided beta value with range 0 < β < 1, where 0 represents un-
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methylated and 1 represents methylated. We transformed the beta value to M value, which
is defined by a logit transformation (M = log2[
β
1−β ]). Therefore methylation characterized by
M value is on continuous scale, similar to mRNA and CNV. If multiple methylation probes
matched to the same gene symbol, we selected one methylation probe as representative,
which had the largest average correlation with other methylation probes of the same gene
symbol. We ended up with 20,147 methylation probes with unique gene symbols.
We filtered out 50% low expression genes (unexpressed genes) and then 50% low variance
genes (non-informative genes). 50% low expression genes are genes with the lowest 50%
mean of gene expression across samples and 10,250 genes remained after this filtering step.
50% low variance genes are genes with the lowest 50% variance of gene expression across
samples and 5,125 genes remained after this filtering step. We obtained 4,815 CNV features
and 5,035 methylation features by matching to the 5,125 gene symbols. The features from
three different omics datasets that shared the same cis-regulatory annotation (same gene
symbol) were grouped together to form 5,125 feature groups. In this case, each group
had one mRNA gene expression, one CNV gene and/or one methylation probe. Each group
contained candidate multi-omics regulatory information because CNV and methylation could
potentially regulate mRNA expression. We applied IS-Kmeans with α = 0.5, sparse K-
means by directly merging three omics datasets together as well as iCluster. Number of
clusters K was set to be 5 since it was well established that breast cancer has 5 subtypes
by PAM50 definition (Parker et al., 2009). For a fair comparison, we selected the tuning
parameter for each method such that number of selected features are close to 2,000.
For evaluation purpose, we investigated three categories of groups among selected fea-
tures: G1, G2 and G3. G3 represents feature groups (gene symbol) where all three types
(mRNA, CNV and methylation) of features are selected. Similarly, G2 represents feature
groups (gene symbol) where only two types of features are selected; G1 represents feature
groups (gene symbol) where only one type of feature is selected; We also compared the clus-
tering result with PAM50 subtype definition in terms of ARI. The result is shown in Table 9.
Clearly, IS-Kmeans obtained more G2 and G3 features than sparse K-means and iCluster.
This is biologically more interpretable but not surprising since IS-Kmeans incorporated the
multi-omics regulatory information and we expected feature of the same group were en-
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couraged to come out together. Besides, IS-Kmeans has higher ARI compared to sparse
K-means and iCluster, indicating the clustering result of IS-Kmeans is closer to PAM50
definition than sparse K-means and iCluster. The 5 by 5 confusion table of IS-Kmeans
clustering result and PAM50 subtypes is shown in supplementary Table 14. One should note
the the ARI for all these three methods are not very high. This could be because PAM50 was
defined by gene expression only and in our scenario we integrated multi-omics information.
The heatmaps of IS-Kmeans result is shown in Figure 10B. In terms of computing time,
IS-Kmeans is nearly 20 times faster than iCluster.
3.4.3 Integrating METABRIC Breast cancer mRNA and CNV
We tested the performance of IS-Kmeans in another large breast cancer multi-omics (sample
size n=1,981) dataset METABRIC (Curtis et al., 2012) with mRNA expression (llumina
HumanHT12v3) and CNV (Affymetrix SNP 6.0 chip) and survival information. The datasets
are available at https://www.synapse.org/#!Synapse:syn1688369/wiki/27311. There
were originally 49,576 probes in gene expression. If multiple probes matched to the same
gene symbol, we selected the probe with the largest IQR (interquartile range) to represent
the gene. After mapping the probes to gene symbols, we obtained 19,489 mRNA expression
features and 18,538 CNV features, which shared 1981 samples. After filtering out 30%
low expression mRNA based on mean gene expression across samples and then 30% low
variance mRNA based on variance of gene expression across samples, we ended up with
9,504 mRNA features. We obtained 8,696 CNV feature symbols by matching with mRNA
feature symbols. Therefore, we had totally 18,200 features and 9,504 feature groups (share
the same gene symbol) among 1,981 samples.
We applied IS-Kmeans with α = 0.5, sparse K-means by directly merging three omics
dataset together as well as iCluster. Number of clusters K was set to be 5 (same reason in
TCGA). For a fair comparison, we selected the tuning parameter for each method such that
number of selected features are close to 2,000. For evaluation purpose, we similarly defined
two categories of groups among selected features. G2 represents feature groups (gene symbol)
where both types of features are selected and G1 represents feature groups (gene symbol)
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where only one type of feature is selected. We also compared the clustering result with
PAM50 subtype definition in terms of ARI. The result is shown in Table 10.
Similar to the TCGA example in Section 3.4.2, IS-Kmeans obtained more G2 features
than sparse K-means and iCluster. The log-rank test of survival difference for the clustering
result defined by IS-Kmeans is more significant than sparse K-means and iCluster. Fur-
thermore, IS-Kmeans has higher ARI compared to sparse K-means and iCluster, indicating
the clustering result of IS-Kmeans is closer to PAM50 definition than sparse K-means and
iCluster. The 5 by 5 confusion table of IS-Kmeans clustering result and PAM50 subtypes
is in supplementary Table 15. In terms of computing time, IS-Kmeans and sparse K-means
are much faster than iCluster.
3.4.4 Three leukemia transcriptomic datasets using pathway database as prior
knowledge
In the simulations and applications so far (Section 3.4.1-3.4.3), we have focused on using
cis-regulatory mechanism as grouping information for integrating multi-level omics data for
sample clustering. In this subsection, we present a different but commonly encountered
application of pathway-guided clustering in single transcriptomic study. Specifically, we use
pathway information from databases to provide prior overlapping group information (i.e.
a pathway is a group containing tens to hundreds of genes and two pathways may contain
overlapping genes). A transcriptomic study is used for sample clustering with the overlapping
group information. We apply IS-Kmeans to three leukemia transcriptomic datasets (Verhaak
et al. (2009), Balgobind et al. (2011) and Kohlmann et al. (2008)) separately and using three
pathway databases (KEGG, BioCarta and Reactome) independently, generating nine IS-
Kmeans clustering results (see Table 11). Table 2 shows a summary description of the three
leukemia transcriptomic studies.
We only considered samples from acute myeloid leukemia (AML) with three fusion gene
subtypes: inv(16) (inversions in chromosome 16), t(15;17) (translocations between chro-
mosome 15 and 17), t(8;21) (translocations between chromosome 8 and 21). These three
gene-translocation AML subtypes have been well-studied with different survival, treatment
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response and prognosis outcomes. Since the three subtypes are observable under micro-
scope, we treated these class labels as the underlying truth to evaluate the clustering per-
formance. The expression data for Verhaak, Balgobind ranged from around [3.169, 15.132]
while Kohlmann ranged in [0, 1]. All the datasets were downloaded directly from NCBI GEO
website. Originally there were 54,613 probe sets in each study. For each study, we removed
genes with any missing value in it. If multiple microarray probes matched to the same gene
symbol, we selected the probe with the largest interquartile range (IQR) to represent the
gene. We ended up with 20,154 unique genes in Verhaak and 20,155 unique genes in Balgo-
bind and Kohlmann. We further filtered out 30% low expression genes in each study, which
were defined as 30% of genes with the lowest mean expression. We ended up with 14,108
unique genes in each study.
We obtained the three pathway databases (BioCarta, KEGG and Reactome) from
MSigDB (http://www.broadinstitute.org/gsea/msigdb/collections.jsp#C2) as the
prior group information to guide feature selection in IS-Kmeans. The original pathway sizes
were 217, 186 and 674 for BioCarta, KEGG and Reactome. We only kept pathways with
size (number of genes inside pathway) greater or equal to 15 and less or equal to 200 after
intersecting with 14,108 unique genes. After gene size restriction, we ended up with 114,
160 and 428 pathways for BioCarta, KEGG and Reactome. Note that these pathway groups
have large overlaps (i.e. many genes appear in multiple pathways).
For each of the three studies, we applied IS-Kmeans (with BioCarta, KEGG and Re-
actome as prior group information respectively), sparse K-means and iCluster. Note that
in this example, IS-Kmeans dealt with single omics dataset with prior knowledge. For a
fair comparison, we tuned the parameters so that the number of selected features are close
to 1,000. The result is shown in Table 11. For Verhaak and Kohlmann, IS-Kmeans and
sparse K-means almost recovered the underlying true clustering labels (ARI=0.901-0.932),
while iCluster had relatively smaller ARI (ARI=0.733). We investigated the heatmap of
the clustering result of Verhaak using iCluster (supplementary Figure 15) to understand
reasons of its worse performance (lower ARI) and found that its solution converged to a
stable clustering configuration with clear clustering separation. Thus, the worse clustering
performance in iCluster likely comes from a local optimum solution. For Balgobind, the
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clustering results from IS-Kmeans and sparse K-means had smaller ARI (ARI=0.792) but
iCluster performed even worse (ARI=0.214).
To further evaluate functional annotation of the selected intrinsic genes via each method,
we explored pathway enrichment analysis (Figure 12) using BioCarta database via Fisher’s
exact test. Five methods (iCluster, IS-Kmeans (BioCarta), IS-Kmeans (KEGG), IS-Kmeans
(Reactome), sparse K-means) were compared. Jittered plot of − log10 p-values are shown in
Figure 12. IS-Kmeans (BioCarta) shows the most significant pathways consistently across
three studies, this is somewhat expected since we used BioCarta pathway as prior knowledge
to guide our feature selection. IS-Kmeans (KEGG) and IS-Kmeans (Reactome) also showed
more significant pathways than sparse K-means and iCluster, indicating incorporating prior
knowledge indeed improved feature selection (in the sense that the selected feature are more
biological meaningful). Note that IS-Kmeans (KEGG) and IS-Kmeans (Reactome) did not
have overfitting issue since the test pathway database (BioCarta) was different from the prior
knowledge we utilized. Similarly, the results using KEGG and Reactome as testing pathway
are in supplementary Figure 15.
3.5 CONCLUSION AND DISCUSSION
Cancer subtype discovery is a critical step for personalized treatment of the disease. In
the era of massive omics datasets and biological knowledge, how to effectively integrate
omics datasets and/or incorporate existing biological evidence brings new statistical and
computational challenges. In this dissertation, we proposed an integrative sparse K-means
(IS-Kmeans) approach for this purpose. The existing biological information is incorporated
in the model and the resulting sparse features can be further used to characterize the cancer
subtype properties in clinical application.
Our proposed IS-Kmeans has the following advantages. Firstly, integrative analysis
increases clustering accuracy, statistical power and explainable regulatory flow between dif-
ferent omics types of data. The existing biological information is taken into account by
using overlapping group lasso. Fully utilizing the inter-omics regulatory information and
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external biological information will increase the accuracy and interpretation of the cancer
subtype findings. Secondly, we reformulated the complex objective function into a simplified
form where weighted K-means and ADMM can be iteratively applied to optimize the convex
sub-problems with closed form solutions. Due to the nature of classification EM algorithm
in K-means and close form iteration updates of ADMM, implementation of the IS-Kmeans
framework is computationally efficient. IS-Kmeans only takes 10-15 minutes for 15,000 omics
features and more than 700 subjects on a standard desktop with single computing thread
while iCluster takes almost 4 hours. Thirdly, the resulting sparse features from IS-Kmeans
have better interpretation than features selected from iCluster.
IS-Kmeans potentially has the following limitations. The existing biological information
is prone to errors and can be updated frequently. Incorporating false biological information
may dilute information contained in the data and even lead to biased finding. Therefore,
we suggest not to over-weigh the overlapping group lasso term and choose α = 0.5 to adjust
for the balance between information from existing biological knowledge and information
from the omics datasets. The users can, however, tune this parameter depending on the
strength of their prior belief of the biological knowledge. Another limitation is that IS-
Kmeans can only deal with one cohort with multiple types of omics data. How to effectively
combine multiple cohorts with multi-level omics data will be a future work. R package
“ISKmeans” incorporates C++ for fast computing and it is publicly available on GitHub
https://github.com/Caleb-Huo/IS-Kmeans as well as authors’ websites. All the data and
code presented in this dissertation are also available on authors’ websites.
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Figure 10: Illustration of IS-Kmeans.
(A) Clustering of mRNA (upper heatmap) CNV (middle heatmap) and methylation
(lower heatmap) profiles separately results in different five clusters of breast cancer sub-
types (represented by color bars of five colors). (B) IS-Kmeans merges mRNA (up-
per heatmap) CNV (middle heatmap) and methylation (lower heatmap) and perform
sample clustering. Inter-omics biological knowledge is also taken into account by over-
lapping group lasso. (C) An illustrating example of design of overlapping group lasso
penalty term Ω(z) to incorporate prior knowledge of pathway information. Here Ω(z) =√
1 + 1 + 1/2 + 1
√
z21 + z
2
2 + 1/2× z23 + z26 +
√
1/2 + 1 + 1 + 1
√
1/2× z23 + z24 + z25 + z27 .
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Figure 11: Selection of tuning parameter γ.
This figure was from the simulated dataset in Section 3.4.1 with α = 0.5. X-axis represents
tuning parameter γ. Red curve and left y-axis denote the corresponding gap statistics. Black
curve and right y-axis denote the corresponding number of selected features. The blue dots
(γ = 0.21) represent where the gap statistics is minimized, and the corresponding number
of selected feature is 1778.
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Table 8: Comparison table of simulation with relative effect size f = 0.6.
θ method α ARI Jaccard index AUC # features time [mins]
1 IS-Kmeans
1 0.940 (0.239) 0.781 (0.202) 0.943 (0.138) 1465 0.44
0.95 0.940 (0.239) 0.791 (0.204) 0.945 (0.136) 1483 0.52
0.5 0.940 (0.239) 0.779 (0.202) 0.971 (0.084) 1420 0.56
0.05 0.940 (0.239) 0.946 (0.214) 0.997 (0.012) 1723 0.67
0.2 IS-Kmeans
1 0.940 (0.239) 0.781 (0.202) 0.943 (0.138) 1465 0.44
0.95 0.940 (0.239) 0.783 (0.202) 0.943 (0.138) 1469 0.57
0.5 0.940 (0.239) 0.602 (0.159) 0.943 (0.134) 1105 0.57
0.05 0.940 (0.239) 0.467 (0.096) 0.888 (0.111) 2824 1.2
iCluster 0.374 (0.323) 0.383 (0.274) 1239 26
sparse Kmeans 1 0.312 (0.370) 0.105 (0.101) 896 0.12
sparse Kmeans 2 0.361 (0.424) 0.204 (0.124) 2137 0.13
We simulated B = 100 times and calculated mean and standard deviation of each quantity.
θ denotes the probability grouping information is correct for each feature inside groups.
α is the tuning parameter balancing the emphasis between individual penalty and group
penalty. For each method, we allow its own tuning parameter selection method to optimize
its performance.
Table 9: Comparison of different methods using TCGA breast cancer (K=5).
method ARI nfeature G1 G2 G3 time
ISKmeans 0.379 2066 843 538 49 12.1 mins
SparseKmeans 0.332 2034 1466 284 0 6.85 mins
iCluster 0.272 2475 1725 375 0 3.91 hours
G3 represents feature groups (gene symbol) where all three types of features are selected.
Similarly, G2 represents feature groups (gene symbol) where only two types of features
are selected; G1 represents feature groups (gene symbol) where only one type of feature is
selected; We also compared the clustering result with PAM50 subtype definition in terms of
ARI.
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Table 10: Comparison of different methods using metabric breast cancer (K=5).
method ARI nfeature G1 G2 p value time
ISKmeans 0.233 1882 1494 194 8.29×10−17 38.4 mins
SparseKmeans 0.22 2004 2004 0 3.04×10−13 34.3 mins
iCluster 0.0572 2471 2471 0 0.143 11.8 hours
G2 represents feature groups (gene symbol) where all two types of features are selected; G1
represents feature groups (gene symbol) where only one type of feature is selected; Clustering
result is compared with PAM50 subtype definition in terms of ARI. Survival p-value obtained
from log rank test are given for clustering assignment for each method.
Table 11: Comparison of different methods by ARI for IS-Kmeans
Verhaak Kohlmann Balgobind
method pathway # features ARI # features ARI # features ARI
IS-Kmeans
Biocarta 1009 0.932 1000 0.948 999 0.792
KEGG 1002 0.901 1013 0.948 990 0.792
Reactome 993 0.932 994 0.948 1008 0.792
iCluster 982 0.733 1233 0.504 1020 0.214
sparse K-means 992 0.932 998 0.948 1014 0.792
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Figure 12: Pathway enrichment analysis result for Leukemia BioCarta
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4.0 DISCUSSION AND FUTURE WORK
4.1 DISCUSSION
Clustering analysis is essential to disease subtype discovery, which is a first step toward
personalized medicine. With the accumulation of large amount of genomic data, it is urgent
and practical to combine multiple cohorts/omics types to increase statistical power and
reproducibility. It is also challenging because there are many statistical difficulties. In
this these, we proposed both meta-analysis sparse Kmeans and integrative sparse Kmeans
to tackle this problem. Simulation and real data application both showed promising result.
These works are nice contribution to both statistical and biological community. They are not
only innovative statistical methodologies, but also practice tools for real data applications.
4.2 INTEGRATIVE META SPARSE KMEANS
In this section we want to propose a unified framework extending both meta Sparse Kmeans
and integrative sparse Kmeans. This part is unfinished and left as a future work. This
method will integrate multiple types of omics data and combine multiple cohorts. Several
issues have to be considered simultaneously. 1, combining multiple cohorts. 2, integrating
different omics data types. 3, allowing missing datatype in several cohorts. 4, allowing over-
lapping group information. 5, achieving sparse clustering. We propose tentative objective
function to tackle this problem. Evaluation will be performed in the future.
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min−
∑
j
zj
(
1
S
S∑
s=1
BCSS
(s)
j (C
(s)(K))
TSS
(s)
j
+ λ× fmatchj (M)
)
+ γ1‖z‖1 + γ2Ω(z)
s.t. ‖z‖2 ≤ 1, zj ≥ 0, ∀j.
min−
∑
zjRj + γ1‖z‖1 + γ2Ω(z)
s.t. ‖z‖2 ≤ 1, zj ≥ 0, ∀j, Rj = 1S
∑S
s=1
BCSS
(s)
j (C
(s)(K))
TSS
(s)
j
+ λ× fmatchj (M)
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APPENDIX A
APPENDIX FOR META SPARSE KMEANS
A.1 ALGORITHMS FOR SIMULATED ANNEALING
When the number of studies is large, the space to search for matching clusters across studies
is not viable with exhaustive search. To maximize the matching objective Equation 2.3.4b,
denoted as pi(M), we applied simulated annealing, a stochastic optimization algorithm for
non-convex function (Kirkpatrick et al., 1983). Our configuration space is defined as a
matching matrix, where the columns correspond to the studies, and the rows correspond to
the matched clusters. For example, if the first row of 3 studies is (1,2,1), that means the first
cluster of 1st study, second cluster of 2nd study and first cluster of 3rd study are matched as
one disease subtype. Also denote 0 ≤ β ≤ 1 as the temperature cooling coefficient and αi as
the acceptance rate at temperature Ti, which is defined as:
αi =
total number of acceptance
total number of simulated annealing steps
at each temperature. β will decide how slow the temperature T decreases and balance
between the accuracy of the result and computation speed. η is the acceptance threshold
which decides when the algorithm stops.
The simulated annealing is conducted in the following steps:
1. Start with a high temperature Ti(i = 1).
76
2. At temperature Ti (one simulated annealing step), we perturb the configuration space
by randomly choosing two elements in the cluster matching enumeration M from two
studies and switch their positions, then calculate the new target value pi(Mnew). Accept
the new configuration with probability:
Pacc = min
(
1, exp
(− pi(Mnew)− pi(M old)
T
))
This procedure will be repeated N times (MC steps).
3. Set Ti+1 = Ti × β
4. Repeat Step 2-3 until αi < η,
In our analysis, we used the MC steps N = 300 at each temperature Ti. The temperature
decreasing rate β is 0.9. The simulated annealing stops when the acceptance ratio drops
below η = 0.1 or the total simulated annealing steps exceed 10, 000. The initial temperature
T1 is set as the objective function value of the initial configuration. In case the initial
temperature is too high which result in a high acceptance ratio, we multiply the temperature
with β = 0.7 whenever the acceptance rate αi > 0.5. This will accelerate the convergent
rate at initial steps when the acceptance rate is high.
A.2 COMPARING METASPARSEKMEANS AND PAM50 CLUSTERS ON
METABRIC
PAM50 is currently the most popular transcriptomic subtype definition of breast cancer. The
model consists of 50 intrinsic genes to predict the five subtypes of breast cancer. Among
these 50 genes, 42 appeared in the METABRIC dataset and among these 42 genes, 22
overlapped with 194 genes selected by our MetaSparseKmeans result (Fisher’s exact tests p-
value for overlap enrichment < 2.2×10−16). supplementary Table 12 shows a full comparison
of the two clustering results by PAM50 and MetaSparseKmeans. There are significant
similarity but also discrepancy between the two. Since no underlying truth is known in such
a real application, it is difficult to judge which one is better (although MetaSparseKmeans
generated smaller p-value of survival difference of the subtypes). Conceptually, PAM50 is a
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supervised machine learning result that utilizes class labels determines by many past studies
with prior biological knowledge. On the other hand, MetaSparseKmeans is a pure in silico
clustering approach.
Table 12: Comparison of MetaSparseKmeans clustering and PAM50 clustering results on
METABRIC dataset.
1 2 3 4 5
Basal 8 122 8 10 180
Her2 9 95 67 60 7
LumA 354 1 34 330 0
LumB 16 3 261 205 5
Normal 122 11 10 57 0
Columns: 5 clusters defined by MetaSparseKmeans. Rows: 5 clusters defined by PAM50.
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APPENDIX B
APPENDIX FOR INTEGRATIVE SPARSE KMEANS
B.1 PROOF FOR THEOREM OF IS-KMEANS
Proof of Theorem 3.3.1. Given equal separation ability for each feature R1 = . . . = Rj =
. . . = RJ = R and the proposed design of overlapping group lasso penalty, Equation 3.3.1
becomes
min
C,z
−
J∑
j=1
zjR + γα‖z‖1 + γ(1− α)
∑
1≤g≤G0
(√∑
j∈Jg
1/h(j)
√∑
j∈Jg
1/h(j)× z2j
)
,
subject to ‖z‖2 ≤ 1, zj ≥ 0, ∀j.
First we can take away the constraint zj ≥ 0,∀j. It is easy to see that if any zj < 0, we
can always use −zj to replace the solution and the objective function will decrease. We can
write down the Lagrange function of Equation 3.3.1 after dropping the constraint zj ≥ 0,∀j:
L(z, λ) = −
J∑
j=1
zjR+γα‖z‖1+γ(1−α)
∑
1≤g≤G0
(√∑
j∈Jg
1/h(j)
√∑
j∈Jg
1/h(j)× z2j
)
+λ(‖z‖22−1)
Partial derivative of the Lagrange is:
∂L(z)
∂zj
= −R + γα∂|zj|
∂zj
+ γ(1− α)
∑
1≤g≤G0
(√∑
j′∈Jg
1/h(j′)
I{j ∈ Jg} × 1/h(j)× zj√∑
j′∈Jg 1/h(j
′)× z2j′
)
+ 2λzj
It is easy to verify that z1 = z2 = . . . = zJ = 1/
√
J , λ =
√
J(R−γ)
2
will make ∂L(z)
∂zj
= 0,∀j.
Since the object function is a convex function, according to sufficiency of KKT condition, the
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proposed penalty design will lead to the solution of “Unbiased Feature Selection” principle.
Proof of Theorem 3.3.2. For intrinsic gene set I, we have Rj = R > 0 for j ∈ I. For non-
intrinsic gene set I¯, we have Rj = 0 for j ∈ I¯. Given the proposed design of overlapping
group lasso penalty, Equation 3.3.1 becomes
min
C,z
−
J∑
j=1
zjRI(j ∈ I) + γα‖z‖1 + γ(1− α)
∑
1≤g≤G0
(√ ∑
j∈(Jg∩I)
1/h(j)
√∑
j∈Jg
1/h(j)× z2j
)
,
subject to ‖z‖2 ≤ 1, zj ≥ 0,∀j.
First we can similarly take away the constraint zj ≥ 0,∀j. We can write down the
Lagrange function of Equation 3.3.1 after dropping the constraint zj ≥ 0,∀j:
L(z, λ) =−
J∑
j=1
zjRI(j ∈ I) + γα‖z‖1+
γ(1− α)
∑
1≤g≤G0
(√ ∑
j∈(Jg∩I)
1/h(j)
√∑
j∈Jg
1/h(j)× z2j
)
+ λ(‖z‖22 − 1)
Partial derivative of the Lagrange is:
∂L(z)
∂zj
=−RI(j ∈ I) + γα∂|zj|
∂zj
+
γ(1− α)
∑
1≤g≤G0
(√ ∑
j′∈(Jg∩I)
1/h(j′)
I{j ∈ Jg} × 1/h(j)× zj√∑
j′∈Jg 1/h(j
′)× z2j′
)
+ 2λzj
It is easy to verify that if for j ∈ I, zj = 1/
√
J , j ∈ I¯, zj = 0 and λ =
√
J(R−γ)
2
is a zero
solution to the partial derivative of the Lagrange function. Note here we set the subgradient
∂|zj |
∂zj
= 0 at zj = 0. Since the object function is a convex function, according to sufficiency of
KKT condition, the proposed penalty design leads to “Unbiased Feature Selection” principle.
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B.2 OPTIMIZATION BY KKT CONDITION
There are two optimization problems.
x+g = arg minxg ‖xg‖2 + y>g xg + ρ2‖xg − βg ◦ z‖22
z+ = arg minz−
∑
zjRj −
∑
1≤g≤G y
>
g (βg ◦ z) + ρ2‖x+g − βg ◦ z‖22
subject to ‖z‖2 ≤ 1, zj ≥ 0.
It is a convex optimization problem for x+g with no constraint. The stationarity condition
states that the sub-gradient of the objective function will be 0 at the optimum solution.
Therefore we have:
S(x+g ) + yg + ρ(x
+
g − βg ◦ z) = 0,
where S(v) is the sub-gradient of ‖v‖2 and
S(v) ∈

v
‖v‖2 , if ‖v‖2 ≥ 1
0, otherwise
If we define ag = βg ◦ z − ygρ , it can be derived that x+g = (1 − 1ρ‖ag‖2 )+ag, where (·)+ =
max(0, ·).
The optimization problem for z+ is a convex optimization problem with two constraints.
We first write down the Lagrange function and convert the constrained optimization problem
into an un-constrained optimization problem:
arg min
z
−
∑
j
zjRj −
∑
1≤g≤G
y>g (βg ◦ z) +
ρ
2
‖x+g − βg ◦ z‖22 + u(‖z‖2 − 1)−
∑
j
vjzj
such that u ∈ R, u ≥ 0, vj ∈ R and vj ≥ 0 ∀j. Taking gradient of the Lagrange function
with respect to z and use the constraints, we can derive the solution to this problem. Define
bj =
∑
1≤g≤G ρβ
2
gj and cj =
∑
1≤g≤G
(
ρx+gj + ygj
) ◦mgj, where βg = (βg1,βg2, . . . ,βgJ)>,
xg = (xg1,xg2, . . . ,xgJ)
>, yg = (yg1,yg2, . . . ,ygJ)>, and mg = (mg1,mg2, . . . ,mgJ)>. The
solution is given as following: we define fj(u) = (
Rj+cj
bj+2u
)+. If
∑
j fj(u)
2 < 1, z+j = fj(0).
Otherwise z+j = fj(u) and u is selected s.t. ‖z+‖2 = 1.
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B.3 SUPPLEMENTARY MATERIALS FOR IS-KMEANS
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(a) α = 1
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(b) α = 0.95
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(c) α = 0.05
Figure 13: Selection of tuning parameter γ.
This figure is from the simulated dataset in Section 4.1 with relative effect size f = 0.6 and
θ = 1. Complementary to Figure 2, simulation setting with α = 1, 0.95, 0.05 are evaluated.
X-axis is tuning parameter γ, red curve and left y-axis denote the corresponding gap statis-
tics, black curve and right y-axis denote the corresponding number of selected features. The
blue dots represent where the gap statistics is minimized, and the corresponding number of
selected features are 1548, 1566, 1800.
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Table 13: Comparison table of simulation with relative effect size f = 0.8.
θ method α ARI Jaccard index AUC # features time [mins]
1 IS-Kmeans
1 1.000 (0.000) 0.812 (0.042) 0.995 (0.004) 1461 0.38
0.95 1.000 (0.000) 0.826 (0.041) 0.996 (0.004) 1486 0.49
0.5 1.000 (0.000) 0.904 (0.032) 0.999 (0.001) 1627 0.52
0.05 1.000 (0.000) 1.000 (0.000) 1.000 (0.000) 1800 0.57
0.2 IS-Kmeans
1 1.000 (0.000) 0.812 (0.042) 0.995 (0.004) 1461 0.38
0.95 1.000 (0.000) 0.771 (0.045) 0.995 (0.004) 1388 0.55
0.5 1.000 (0.000) 0.835 (0.038) 0.994 (0.004) 1512 0.49
0.05 1.000 (0.000) 0.495 (0.021) 0.938 (0.004) 2815 1
iCluster 0.722 (0.325) 0.672 (0.198) 1906 26
sparse Kmeans 1 0.931 (0.209) 0.159 (0.073) 5777 0.13
sparse Kmeans 2 0.898 (0.253) 0.070 (0.035) 506 0.11
We simulated B = 100 times and calculated mean and standard deviation of each quantity.
θ denotes the probability grouping information is correct for each feature inside groups.
α is the tuning parameter balancing the emphasis between individual penalty and group
penalty. For each method, we allow its own tuning parameter selection method to optimize
its performance.
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(a) IS-Kmeans Biocarta (b) IS-Kmeans KEGG (c) IS-Kmeans Reactome
(d) Sparse K-means (e) iCluster
Figure 14: Heatmap of Verhaak by IS-Kmeans.
Heatmap of Verhaak by IS-Kmeans (using BioCarta, KEGG and Reactome pathway
databases as prior knowledge), Sparse K-means and iCluster. Number of selected features
are: 1,009 for Figure S14(a), 1,002 for Figure S14(b), 993 for Figure S14(c), 982 for Fig-
ure S14(d), 992 for Figure S14(e).
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Figure 15: Pathway enrichment analysis result for Leukemia using KEGG and Reactome
as testing database.
Table 14: Comparison of IS-Kmeans and PAM50 clustering results on TCGA multi-omics
dataset.
1 2 3 4 5
Basal 0 4 8 135 13
Her2 4 54 4 0 42
LumA 59 25 153 0 0
LumB 86 89 13 0 1
Normal 1 6 68 0 3
Columns: five clusters defined by IS-Kmeans. Rows: five clusters defined by PAM50.
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Table 15: Comparison of IS-Kmeans and PAM50 clustering results on METABRIC multi-
omics dataset.
1 2 3 4 5
Basal 0 69 24 0 235
Her2 8 133 78 19 0
LumA 343 2 146 228 0
LumB 112 5 147 226 0
Normal 45 29 106 9 11
Columns: five clusters defined by IS-Kmeans. Rows: five clusters defined by PAM50.
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Table 16: Comparison table of perturbation analysis for IS-Kmeans with f = 0.8.
θ method α ARI Jaccard index AUC # features time [mins]
1 IS-Kmeans
1 0.980 (0.078) 0.817 (0.066) 0.973 (3e-02) 1701 0.53
0.95 0.980 (0.078) 0.825 (0.065) 0.975 (3e-02) 1715 0.64
0.5 0.980 (0.078) 0.905 (0.063) 0.990 (1e-02) 1652 0.59
0.05 0.984 (0.068) 0.993 (0.005) 1.000 (1e-04) 1812 0.67
0.2 IS-Kmeans
1 0.980 (0.078) 0.817 (0.066) 0.973 (3e-02) 1701 0.52
0.95 0.980 (0.078) 0.817 (0.065) 0.973 (3e-02) 1708 0.7
0.5 0.980 (0.078) 0.777 (0.058) 0.973 (3e-02) 1863 0.68
0.05 0.980 (0.078) 0.496 (0.032) 0.911 (2e-02) 3002 1.3
iCluster 0.717 (0.291) 0.679 (0.186) 1657 27
sparse Kmeans 1 0.824 (0.285) 0.096 (0.026) 2065 0.13
sparse Kmeans 2 0.826 (0.291) 0.119 (0.043) 6139 0.16
In the simulation setting Step a3, the template gene expression is simulated from a t-
distribution with degree of freedom 3, location parameter 9 and scale parameter 2. In Step a4,
we set relative effect size f = 0.8. In Step a5, X ′skmi is simulated from a t-distribution with
degree of freedom 3, location parameter µ′skm and scale parameter σ
2
1. We simulated B = 100
times and calculated mean and standard deviation of each quantity. θ denotes the probabil-
ity grouping information is correct for each feature inside groups. α is the tuning parameter
balancing the emphasis between individual penalty and group penalty. For each method, we
allow its own tuning parameter selection method to optimize its performance.
87
Table 17: Comparison table of perturbation analysis for IS-Kmeans with f = 0.6.
θ method α ARI Jaccard index AUC # features time [mins]
1 IS-Kmeans
1 0.798 (0.368) 0.592 (0.260) 0.811 (0.204) 1455 0.55
0.95 0.798 (0.368) 0.601 (0.262) 0.817 (0.200) 1474 0.68
0.5 0.793 (0.368) 0.710 (0.292) 0.899 (0.126) 1426 0.68
0.05 0.801 (0.358) 0.914 (0.150) 0.992 (0.013) 1760 0.91
0.2 IS-Kmeans
1 0.809 (0.352) 0.600 (0.249) 0.829 (0.190) 1468 0.55
0.95 0.809 (0.352) 0.600 (0.248) 0.829 (0.189) 1478 0.74
0.5 0.809 (0.352) 0.573 (0.227) 0.832 (0.184) 1678 0.74
0.05 0.809 (0.352) 0.397 (0.122) 0.791 (0.147) 2900 1.5
iCluster 0.300 (0.313) 0.261 (0.196) 790 27
sparse Kmeans 1 0.334 (0.377) 0.243 (0.202) 4755 0.17
sparse Kmeans 2 0.187 (0.304) 0.022 (0.036) 725 0.13
In the simulation setting Step a3, the template gene expression is simulated from a t-
distribution with degree of freedom 3, location parameter 9 and scale parameter 2. In Step a4,
we set relative effect size f = 0.6. In Step a5, X ′skmi is simulated from a t-distribution with
degree of freedom 3, location parameter µ′skm and scale parameter σ
2
1. We simulated B = 100
times and calculated mean and standard deviation of each quantity. θ denotes the probabil-
ity grouping information is correct for each feature inside groups. α is the tuning parameter
balancing the emphasis between individual penalty and group penalty. For each method, we
allow its own tuning parameter selection method to optimize its performance.
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